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Abstract 
 
Using living cells to treat disease is known as cell therapy and holds the potential to 
revolutionize healthcare. An increasing number of cell-based products are approaching the 
late clinical development phase, with human mesenchymal stem cells, which have 
chondrogenic, osteogenic and adipogenic differentiation capacity, being one of the most 
widely studied. For these new medicinal products, preserving their therapeutic potential 
throughout the supply chain is challenging. Current approaches are based on 
cryopreservation, where cells are cooled to -80 °C or lower, on hypothermic preservation, 
where cells are cooled to 2-8 °C, and on controlled room temperatures, with cells at 15-25 °C. 
However, these methods suffer from limitations and alternative approaches are required.  
The aim of this thesis was to investigate a novel temperature range (26-37 °C) for storage and 
transportation and, for the first time, to combine temperature with a variable oxygen tension 
(3-20 %) over a simulated shelf life of 5 or 7 days. Two models were investigated: 
undifferentiated human bone marrow derived mesenchymal stem cells and cartilage discs 
derived from these cells. The investigation was based on the use of a statistical design of 
experiment where temperature, oxygen and storage duration are the input factors while 
viability, metabolite concentrations and gene expression are the output factors.   
The results showed that temperature and oxygen modulate metabolic activity and subsequent 
differentiation potential, with interaction effects between temperature and oxygen being 
readily identifiable. Predictive models were subsequently developed, with case studies 
demonstrating how such models can be used as a decision support tool for the design of a 
transportation device for mesenchymal stem cells and their differentiated products.  
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Overall, this thesis demonstrates the need for a multifactorial approach for the development 
of a storage and transportation solution of cell-based medicinal products and offers guidance 
as to how this may be possible. 
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Chapter 1  
 
 
Introduction 
 
 
 
 
1.1 Cell therapy industry overview 
 
 
 
 
 
 
Historically human cells have only been considered as the microscopic building blocks of the 
human body and it was not until the late 1950s that Dr. E. Donnall Thomas demonstrated that 
bone marrow can be used to cure patients dying from blood cancers (Appelbaum, 2007). 
The administration of human cells to treat diseases is referred to as cell therapy (Mason, 
Brindley, Culme-Seymour, & Davie, 2011). Cell therapy has the great potential to target 
diseases that cannot be targeted with small molecules or biologics. However, their 
manufacturing is both more expensive and more complex (Salmikangas et al., 2015). 
Compared to traditional biologics where cell lines, such as Chinese Hamster Ovary (CHO) 
and NS0, are used to produce the therapeutic protein that is normally secreted, for cell-based 
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medicinal products the actual living cell is the product. In Europe, cell-based products in 
which cells have been either substantially manipulated or are not intended to be used for the 
same essential function(s) in the recipient and the donor are regulated as medicinal products 
under the legal framework of Advanced Therapy Medicinal Products (ATMPs) 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_00
0296.jsp) . In the US, cell-based products are regulated as biologics 
(http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/G
uidances/CellularandGeneTherapy/ ). Many governments worldwide have been investing in 
translating the last two decades of basic research into commercially viable cell therapy 
products. Examples are Japan, the US, Canada and, in Europe, the UK, Germany and Spain 
(https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/32459/11-
1056-taking-stock-of-regenerative-medicine.pdf ). Japan enacted a new Regenerative 
Medicine Law regulating the development, approval and use of regenerative medicine 
products in November 2014. Conditional approvals can now be granted based on safety and 
efficacy data from Phase II clinical trials, instead of full Phase III programs, and allow for 
commercial sales for up to seven years. This new approval process will encourage the 
development of novel regenerative therapies and will also speed up product approvals 
(Konomi, Tobita, Kimura, & Sato, 2015). Big Pharmaceutical companies are also 
increasingly interested and investing in developing these new kinds of drugs with a market 
which is estimated to grow at a rate of roughly 40% from 2015 to 2020. 
http://www.prnewswire.com/news-releases/stem-cell-therapy-market-growing-at-395-cagr-
worldwide-to-2020-276525411.html .  
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1.2 Human cells as active pharmaceutical ingredients 
 
A broad spectrum of cell types with different levels of ex-vivo manipulations are currently 
being evaluated in clinical trials (www.clinicaltrials.gov). These can be divided into two main 
categories: (1) stem cell-based and (2) non-stem cell-based therapies.  
Stem cells pose the unique capacity to self-renew and to differentiate into cells of different 
lineages under specific stimuli (Ying et al., 2008). For these properties, they have generated 
great interest for drug screening, human tissue research and cell-based therapies (Ebert & 
Svendsen, 2010). Depending on their origin, they can be classified into two categories: adult 
and embryonic. Adult stem cells have limited proliferation and differentiation potential in 
vitro compared to embryonic stem cells (Ramalho-Santos et al., 2002). Embryonic stem cell 
(ESCs) are capable of differentiating into derivatives of all three germ layers, ectoderm, 
endoderm and mesoderm while maintaining high proliferation potential (Rippon & Bishop, 
2004). This ability makes them an excellent candidate for use as a therapeutic agent as well 
as for toxicology testing and to investigate genetic disease (Deshmukh et al., 2012). As 
atherapeutic agent, ESC-based therapies are under development to treat diseases such as 
diabetes (D’Amour et al., 2006), macular degeneration (Schwartz et al., 2012) and 
Parkinson’s disease (Brederlau et al., 2006). Ethical concerns associated with the use of ESCs 
along with the risk of teratoma formation in vivo and immunogenicity have limited their use 
for clinical application (M. J. Martin, Muotri, Gage, & Varki, 2005). In 2006, a new type of 
pluripotent stem cell was announced by Takahashi and Yamanaka (Takahashi & Yamanaka, 
2006). Their study revealed the possibility for mouse fibroblast cells to be transfected with 
lentiviral vectors carrying Oct-4, Sox-2, Klf-4 and c-myc to become pluripotent. These cells 
are called “Induced Pluripotent stem cells” (iPSCs). This finding were later replicated in 
human cells (Pei, Xu, Zhuang, Tse, & Esteban, 2010). This new type of cell generated great 
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interest mainly for drug screening purposes. They have been tested on humans but the first 
clinical trial in Japan was suspended due to genomic issues 
(http://www.nature.com/news/next-generation-stem-cells-cleared-for-human-trial-1.15897). 
The most widely studied type of adult stem cells isolated from human tissue are referred to as 
mesenchymal stromal/stem cells (MSCs). On the other hand, the most investigated type of 
non-stem cell for clinical application are T-cells.  T-cells can be engineered to overcome the 
natural protection mechanisms and target tumour cells either via a chimeric antigen receptor 
(CAR) or by affinity-enhanced T-cell receptor (TCR). The former has proven to be more 
effective for haematological malignancies as it can target antigen on the cell surface. The 
latter has the potential to target intracellular antigens and this makes it, potentially, a more 
suitable candidate for treating solid tumour (Fedorov, Sadelain, & Kloss, 2014). 
 
 
 
1.3 Human mesenchymal/stromal stem cells 
 
MSCs were isolated for the first time in the mid-1960s from rat bone marrow by Friedenstein 
and colleagues (Friedenstein et al. 1966). Since then, the presence of MSCs has been 
documented in many human specialized tissues and organs where they normally reside as 
rare and quiescent populations (Conget & Minguell, 1999).  
Human MSCs (hMSCs) show many interesting properties that make them a good candidate 
for therapeutic applications, such as the ability to self-renew and to differentiate into 
mesodermal lineages (cartilage, bone, fat and muscle) (Nombela-Arrieta, Ritz, & Silberstein, 
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2011) (Fig.1.1). Their ability to trans-differentiate into cells of all three germ layers 
(mesodermal, endodermal and ectodermal) has also been demonstrated (Sasaki et al., 2008). 
Bone marrow is one of the most common sources of hMSCs, where they are involved in 
tissue homeostasis and in the turnover of skeletal cell types (Bruder, Fink, & Caplan, 1994). 
The yield of hMSCs that can be isolated from bone marrow is, however, very low, ranging 
from 0.01 to 0.001 % of all cells (Panchalingam, Jung, Rosenberg, & Behie, 2015). Adipose 
tissue is, on the other hand, a more abundant source of hMSCs (Keung, Nelson, & Conrad, 
2013). 
Other sources include umbilical cord blood (H.-S. Wang et al., 2004), amniotic fluid 
(Sessarego et al., 2008), placenta (Makhoul, Chiu, & Cecere, 2013), synovium (Arufe, De la 
Fuente, Fuentes, de Toro, & Blanco, 2010) and peripheral blood (Kassis et al., 2006). 
Compared to bone marrow, adipose tissue and umbilical cord blood can be isolated without a 
highly invasive procedure (Zhang et al., 2011). 
However, hMSCs from different tissues show some differences in their differentiation 
potential and properties. Kern et al. compared hMSCs from umbilical cord blood (UCB), 
adipose tissue (AT) and bone marrow (BM) and found that UCB-MSCs show no adipogenic 
potential, unlike BM- and AT-MSCs (Kern, Eichler, Stoeve, Klüter, & Bieback, 2006). On 
the other hand, UCB-MSCs showed the highest proliferation capacity and therefore they are a 
source that facilitates high cell yields that might be necessary for therapeutic applications on 
a large scale (Simaria et al., 2014). 
Currently, the methods used to characterize these cells are based on the International Society 
of Cellular Therapy guidelines (Dominici, 2006). According to these, the minimal criteria for 
hMSC characterization are the following: (a) MSCs must be plastic–adherent when 
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maintained in standard culture conditions and develop Colony-Forming Unit-Fibroblasts 
(CFUFs) (b) MSCs must express CD105, CD73 and CD90 and lack expression of CD45, 
CD34, CD14 or CD11b, CD79 or CD19 and HLA-DR surface molecules and; (c) MSCs 
must also demonstrate tri-lineage differentiation into osteocytes, adipocytes and chondrocytes 
in vitro (Dominici et al., 2006).  
However, there is considerable evidence showing that such marker-based classification is not 
sufficient to distinctively define the cellular composition for a MSC-based product 
(Mendicino, Bailey, Wonnacott, Puri, & Bauer, 2014). 
 
Fig.1.1 Schematic summarizing the main sources and properties of mesenchymal stem cells  
(modified from (Eberli et al., 2014)). 
 
Clinical use of hMSC 
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The most commonly investigated source of hMSCs for clinical applications are bone marrow, 
adipose tissue and umbilical cord (clinicaltrial.gov).  
hMSCs have the potential to home to and engraft at sites of injury where they can stimulate 
endogenous differentiation of resident cells towards tissue regeneration (Chamberlain, Fox, 
Ashton, & Middleton, 2007), or secrete a wide spectrum of bioactive molecules, such as 
cytokines, that will exert the therapeutic effect (Kinnaird et al., 2004). This second 
mechanism was also suggested by clinical trials where hMSCs lack long term homing and 
differentiation into the target tissue but showed that inflammation was reduced in disease 
models like myocardial infarction (Lee et al., 2009). 
hMSCs can be administered either intravenously (IV) or directly implanted into the site. The 
former mechanism relies on the ability of the hMSCs to migrate across the endothelium and 
home to injured tissues in a manner similar to migration of leukocytes to sites of 
inflammation (Chamberlain et al., 2007). The latter is, however, preferred when there is a 
need to reduce the risk of cell migration to other sites in the body (Barbash et al., 2003). 
Numerous pre-clinical and clinical studies are investigating the use of hMSC to induce bone 
regeneration, when the natural ability of bone to self-repair has been compromised by trauma 
or disease (X. Wang et al., 2013).  
In addition to bone regeneration, hMSCs are also being used to target cartilage regeneration, 
which , unlike bone, has a very limited self-healing capacity (Steinert, Rackwitz, Gilbert, 
Noth, & Tuan, 2012). In most cases, hMSCs are used in combination with hydrogels that can 
be directly injected into the joint (Spiller, Maher, & Lowman, 2011).  
hMSCs have also shown promising signs of clinical efficacy for cardiac regeneration 
(Mathiasen et al., 2015) , (Bartunek et al., 2016).  
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Other applications include treatments for graft-versus-host-disease (GvHD) (Munneke et al., 
2015)and Crohn’s disease (Panés et al., 2016), (Carlsson, Schwarcz, Korsgren, & Le Blanc, 
2015).Currently (August 2016) there are over 600 clinical trials using hMSCs for a wide 
range of disease (clinicaltrial.gov, results for “mesenchymal stem cells”). 
 
1.4  Manufacturing and delivery of cell based medicinal products 
 
Despite the fact that cell therapy manufacturing shares some similarities with other 
biopharmaceuticals (such as monoclonal antibodies or vaccines), the use of human cells as 
therapeutic agents poses some challenges ( Martin, Simmons, & Williams, 2014). Cell based 
therapies can be also divided into two broad groups: autologous (where the product is derived 
from the patient’s own cell) and allogeneic (where the product is derived from one universal 
donor).  
The differences between autologous and allogeneic products translate into two different 
manufacturing models. For autologous cell therapy products, the biopsy isolated from the 
patient needs to be processed and the cell expanded to a sufficient number to generate adequate 
patient doses and to allow quality tests. One batch of product will be used for one patient and 
to increase the number of batches produced in a given time, more culture devices can be run in 
parallel (Hourd, Ginty, Chandra, & Williams, 2014). In order to reduce the risk of cross-
contamination, without having to dedicate one process room to processing one product for one 
patient, fully closed, automated and disposable processing systems should be used (Trainor, 
Pietak, & Smith, 2014). Allogeneic cell therapy manufacturing, on the other hand, is more 
similar to traditional biopharmaceutical manufacturing and production scale-up has been 
demonstrated (Heathman et al., 2015). The output is increased by increasing the volume of the 
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bioreactor, or the surface available for the cells to attach and grow so that more cells can be 
processed for each batch (Ma, Tsai, & Liu, 2016). Due to economy of scale, the latter is usually 
more cost-effective (Simaria et al., 2014). The need to scale up the production will increase 
along the clinical development of the product, as the cell therapy product approaches phase III 
and then the commercial stage, the demand will also increase. The difference in the whole 
bioprocessing of autologous and allogeneic products can be directly linked to the difference 
between these two types of therapies. Autologous cell therapies are patient specific and they 
carry a lower risk of immune reaction. On the other hand, they require two procedures (one for 
the biopsy harvest and the other for the administration of the therapy) and they are not suitable 
for emergency procedures as normally it takes two to three weeks after the biopsy for the cell 
product to be ready for implantation. The limited amount of “raw material” makes product, 
process and release tests development very difficult and expensive. Logistics is also more 
complicated due to the risk of mishandling or damage during transportation of both the biopsy 
from the hospital to the manufacturing site and the product back to the hospital.  As one batch 
corresponds to one patient, autologous products can be also characterized by high batch to 
batch variability. Quality control assays have to be performed for every batch and, therefore, 
every patient dose. This will increase the costs of the therapy. Automation of some of the 
manufacturing steps is feasible but it can only be successfully achieved by adoption of a fully 
closed disposable system which enables parallel processing of multiple batches 
simultaneously, without the risk of cross-contamination (Trainor et al., 2014).  Allogeneic cell-
based therapies, on the other hand, are more similar to the traditional biopharma model where 
an “off-the-shelf” product is delivered to the hospital. Cells extracted from one universal donor 
are expanded and many patient doses are made from each donor. It is usually easier to develop 
robust, high quality manufacturing procedures for allogeneic products. There is also no need 
for painful harvesting procedures for the patient as the necessary cells are derived from one 
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universal donor. Historically, allogeneic cell therapies have been accompanied by the 
administration of immune suppressant drugs. However, the use of hMSCs, which show very 
low level of immunogenicity, negates the need for life-threatening immune-suppressant 
(Consentius, Reinke, & Volk, 2015).  
 
Figure 1.2 compares the autologous and allogeneic bioprocessing of cell therapy. For 
allogeneic products, a “master cell bank” (MCB) needs to be developed from one universal 
donor and quality tested. From one lot of MCB, a “working cell bank” can be expanded and 
from this come all patient doses (Brandenberger et al., 2011). 
 
 
Fig. 1.2 Allogeneic versus autologous manufacturing models. Autologous products are patient 
specific; one batch will correspond to one patient. Starting from a biopsy isolated from the 
patients, cells will need to be processed to generate the number of doses required for that 
treatment and to allow quality testing. For allogeneic products, cells from one universal donor 
are isolated, validated and generate a master cell bank. This is further expanded into a working 
cell bank. When a production lot is required, patient doses will be generated from the working 
cell bank and will be used to treat multiple patients (modified from (Brandenberger et al., 2011)). 
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For both types of products, the biological function of the cells needs to be preserved across 
the entire supply chain. A validated potency assay should be in place to confirm that a 
product of consistent quality is manufactured and it is also necessary to establish the shelf-life 
of the product (C. A. Bravery et al., 2013). 
 
 
 
1.5  Preservation methods for cell based medicinal products  
The preservation of the viability and biological function of a cell-based product, also referred 
to as bio-preservation (Baust & Baust, 2007),  is imperative for the delivery to the patients. 
This encompasses storage for transportation of the products from the manufacturing site to 
the clinic as well as storage for quality testing necessary for product release (Coopman & 
Medcalf, 2014). Autologous products are characterized by a circular distribution system as 
the “raw” materials are harvested from the patient, processed and then administered back to 
the same patient. Allogeneic products tend to have a more linear distribution system as doses 
are expanded from a donor and are then available for patients. Given their nature, allogeneic 
products normally require a longer shelf-life compared to autologous products; the former 
need to be used off-the-shelf while the latter are produced on demand for a specific patient. 
However, the need to treat a patient multiple times with the same batch of cells along with an 
increased flexibility in terms of scheduling of the treatment lead to a longer shelf life being 
preferable also for autologous product (Rayment & Williams, 2010) . Table 1.1 lists a 
number of marketed cell therapy products with their preservation method.
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Table 3.1 List of selected marketed cell-based medicinal products with their final formulation, shelf-life and storage conditions. PAP-GM-CSF= 
prostatic acid phosphatase-granulocyte–macrophage-colony-stimulating factor, DMEM=Dulbecco’s modified eagles medium 
Product Company Active ingredient Final Formulation Shelf life and storage 
conditions 
Reference 
Provenge® 
(Sipuleucel-T) 
Dendreon ≥ 50 x 106 autologous CD54+ 
cells/250 mL activated with 
PAP-GM-CSF 
Lactated Ringer's solution 
(NaCl, NaC3H5O3, KCl, 
CaCl2). Dispersion for infusion  
18 hours at 2 °C-8°C   http://www
.fda.gov/do
wnloads/bio
logicsblood
vaccines/cel
lulargenethe
rapyproduct
s/approvedp
roducts/ucm
214565.pdf 
ChondroCelect® Tigenix 4x106 autologous human 
cartilage cells/ 0.4 ml 
DMEM 48 hours at 15°C-25°C  http://www.
ema.europa.
eu/docs/en_
GB/docume
nt_library/E
PAR_-
_Public_ass
essment_rep
ort/human/0
00878/WC5
00026035.p
df  
MACI® Vericel 0.5 x106-1x106 autologous 
cultured chondrocytes/ cm2 
porcine derived Type I/III 
collagen membrane 
DMEM, HEPES adjusted for 
pH with HCl or NaOH and 
osmality with NaCl.  
6 days at ≤ 37°C   http://www.
ema.europa.
eu/docs/en_
GB/docume
nt_library/E
PAR_-
_Public_ass
essment_rep
ort/human/0
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02522/WC5
00145888.p
df 
Carticel  Vericel 12 x 106  chondrocytes  0.4 ml Buffered cell culture 
media (DMEM) 
Viability up to 72 hours 
when vial is kept in 
secondary packaging at 
room temperature  
 http://www.
fda.gov/dow
nloads/Biol
ogicsBlood
Vaccines/Ce
llularGeneT
herapyProd
ucts/Approv
edProducts/
UCM10933
9.pdf 
Apligraf Organogenesis human fibroblasts (dermal cells) 
and human keratinocytes 
(epidermal cells) 
supplied as a circular disk 
approximately 75 mm in 
diameter and 0.75 mm thick in 
agarose nutrient medium 
which contains agarose, L-
glutamine, 
hydrocortisone,human 
recombinant insulin, 
ethanolamine, O-
phosphorylethanolamine, 
adenine, selenious acid, 
DMEM powder, HAM’s F-12 
powder, sodium bicarbonate, 
calcium chloride, and water for 
injection 
15 days from the packaging 
date, when stored within the 
closed shipper/storage box 
at a controlled room 
temperature 20°C - 23°C 
until use 
 http://www.
apligraf.com
/professiona
l/pdf/Apligr
af_Storage_
FAQs.pdf 
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Prochymal Mesoblast Liquid containing 100 x 106 
hMSCs per 15 mL. The diluted 
product contains 2.5 x 106 
hMSCs per mL 
10% Dimethyl sulphoxide 
(DMSO) , 5% human serum 
albumin (HSA) in Plasma-Lyte 
A. Intravenous infusion 
24-month shelf-life stored in 
liquid nitrogen (LN2) vapor 
phase temperature 
(≤−135°C)  
 http://www.
hc-
sc.gc.ca/dhp
-
mps/prodph
arma/sbd-
smd/drug-
med/sbd_sm
d_2012_pro
chymal_150
026-eng.php 
Holoclar  Chiesi 
Farmaceutici 
300,000 to 1,200,000 viable ex-
vivo expanded autologous   
human corneal epithelial cells 
including on average 3.5% 
(0.4% to 10%) limbal stem cells 
physiological transport 
medium (containing DMEM), 
supplemented with L-
glutamine 
36 hours transport stable 
temperature (15°C-25 °C) 
http://www.
ema.europa.
eu/docs/en_
GB/docume
nt_library/E
PAR_-
_Public_ass
essment_rep
ort/human/0
02450/WC5
00183405.p
df 
  
Dermagraft Organogenesis Human fibroblast-derived 
dermal substitute 
Cryopreserved. Saline based 
cryoprotectant that contains 10 
% DMSO and bovine serum 
Up to 6 months when stored 
at - 80 °C  
http://www.
dermagraft.c
om/quality/ 
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Body temperature and hypothermic storage 
Human cells are often preserved by lowering the temperature from 37 °C (body temperature) 
to 15°C-25 °C (controlled room temperature) and 2°C-8 °C (refrigerated)(Coopman & 
Medcalf, 2014).  Evidence regarding the efficacy of storage and shipping at body temperature 
is limited and this range is not very widely adopted given the rather limited shelf life of the 
product when kept at 37 °C. Hypothermic preservation is widely used in surgical procedures, 
such as heart by-pass (Baos et al., 2015). By lowering the temperature, cell metabolism  and 
cycle progression is slowed and cells are effectively ‘paused’(Robinson, Picken, & Coopman, 
2014).  This technique has been applied also to red blood cells and peripheral blood products 
that are often stored at 4 °C for 24-48 hours prior to infusion (Acker, 2013). However, cell 
injury post-hypothermia storage has also been documented (Corwin, Baust, Baust, & Van 
Buskirk, 2014). A number of studies have also investigated the production of heat shock 
proteins (HSP), which act as chaperon proteins to prevent cold-induced denaturation 
(Mahmood S Choudhery, Badowski, Muise, & Harris, 2015).  In order to limit cell damage 
during hypothermic storage, and often extend the shelf life of the product,  new formulations 
have been developed, such as intracellular-like HypoThermosol (HTS) (Mathew, Baust, Van 
Buskirk, & Baust, 2004).  Another formulation is based on the encapsulation of the cells in 
alginate for storage at controlled room temperature and it has been successfully applied for  
adipose derived hMSCs (Swioklo, Constantinescu, & Connon, 2016). 
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Cryopreservation  
The standard method for long-term stabilisation of biological cells is freezing at ultra-low 
temperatures (typically using liquid nitrogen). The process is known as cryopreservation and 
is a technique based on lowering the temperature in order to inhibit cellular metabolic and 
biochemical reactions (Baust & Baust, 2007). These are normally slowed down at -80 °C and 
completely halted at temperatures below -150 °C (which requires LN2),which are normally 
used for long-term cell banking.  
In order to prevent cell damage due to ice crystal formation during the cooling phase, the 
addition of cryoprotectants is required (Massie et al., 2014). The most commonly used 
cryoprotectants  are dimethyl-sulfoxide (DMSO) and glycerol (Pogozhykh, Prokopyuk, 
Pogozhykh, & Mueller, 2015).  However, these normally need to be removed prior to 
administration to the patient (Hunt, 2011).  
While viability recovery post-cryopreservation has been documented for many cell types 
(Van Campenhout, Swinnen, Klykens, Devos, & Verhoef, 2014), evidence suggests that a 
number of cell types might not fully recover their biological function (Galipeau, 2013). 
 
 
 
 
Lyophilisation  
Another method to preserve the stability of the cells during storage is lyophilisation 
(dehydration), which is extensively used for protein-based drugs (Frokjaer & Otzen, 2005). 
For human cells, this method has so far been adopted for a very limited number of cell types, 
such as hematopoietic stem cells (Buchanan, Pyatt, & Carpenter, 2010) and red blood cells 
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(Han et al., 2005). Buchanan et al. demonstrated that hematopoietic stem cells could be 
lyophilized with the addition of a stabilizing sugar, trehalose, and preserved at 25 °C for 4 
weeks and that they maintained their clonogenic and differentiation properties (Buchanan et 
al., 2010). 
 
1.6  Statistical Design of Experiment (DoE) for cell therapy development 
 
The concept of Quality by Design (QbD) was introduced by the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for human use 
and provides a modular and “systematic approach to product development that begins with 
predefined objectives and emphasizes product knowledge, process understanding and process 
control, based on sound science and quality risk management” 
(http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html).  
The basic principle of QbD is that quality should be built in the products by design and only 
tested post manufacturing to confirm the pre-desired product attributes. Over the past decade, 
QbD programs have been developed mostly for small molecules but also for some 
biotechnology products, such as monoclonal antibodies and vaccines (Rathore & Winkle, 
2009; Wurth et al., 2016). The adoption of the QbD framework for cell and gene based 
medicinal products has also been proposed (Lipsitz, Timmins, & Zandstra, 2016), although 
the complexity of these products limits its application and its successful implementation still 
needs to be demonstrated.  
Statistical Design of Experiment (DoE) was developed and first used in the early 1920s by 
Sir Ronald Fisher (Montgomery, 2012) and is one of the key tools in the QbD framework.  
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While the common “One Factor at a Time” (OFAT) approach assumes a lack of statistical 
interaction of variables on the process response, DoE uses multivariate design to investigate 
multiple parameters in parallel experimental runs. 
For many bioprocess systems it is common for variables to be interdependent and produce 
statistically and practically significant interactions. In practical terms, this means the response 
to a change in one factor level is often dependent on the level of one or two of the other 
variables.  These effects will not be detected by OFAT experiments.  
DoE is therefore an efficient way to identify a number of statistically significant main and 
interacting factor effects on one or more selected responses. It can also be used to determine 
input parameter ranges that maximize or minimize a selected response variable, whereas 
OFAT often leads to sub-optimal values (Lim et al., 2007). 
The main advantages of DoE over the OFAT approach can therefore be summarized as 
follows:  
1. It requires less resources (experiments, time, material, etc) for the amount of 
information obtained.  This will reduce costs as experiments can be very expensive and time 
consuming. 
2. The estimates of the effects of each factor are more precise. Using more observations 
to estimate an effect results in higher presision (reduced variability). For example, for full and 
fractional factorial designs, all the observations are used to estimate the effect of each factor 
and each interaction (property of hidden replication), while typically only two of the 
observations in a OFAT experiment are used to estimate the effect of each factor.  
3. The interaction between factors can be estimated systematically. Interactions are not 
estimable from OFAT experiments.  
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4. There is experimental information in a larger region of the factor space. This 
improves the prediction of the response in the factor space by reducing the variability of the 
estimates of the response in the factor space, and makes process optimization more efficient 
because the optimal solution is searched for over the entire factor space.  
 
1.7  Scope and aim of research  
 
The development of successful bio-preservation strategies will play a key role in the supply 
chain of cell-based medicinal products (Salmikangas et al., 2015)(Coopman & Medcalf, 
2014). Today, these products tend to be transported via solutions borrowed from biotech 
products, such as vaccines that are shipped at 2-8 °C, or cryopreserved. There is, however, 
increasing evidence that cryopreservation might alter the efficacy of the cell-based drug, as 
suggested by Galipeau et al.(2013) following the failure of a Phase III clinical trial of 
Prochymal for steroid-resistant GvHD to meet its primary clinical endpoint.   
The limited, or lack of, knowledge of how cells will respond to chemical, mechanical and 
physical stimuli hinder the development of cost-effective standards for storage and 
transportation of these products. 
The more complex nature of these ‘living’ drugs and the need to cope with large scale 
distribution supports a deeper investigation of the parameters that will ultimately affect the 
safety and efficacy of the product.  As happened for protein-based drugs, which are sensitive 
to high temperature, shear, oxidative stress and pH changes (Frokjaer & Otzen, 2005), 
enhanced knowledge of the factors influencing the stability of the cell-based drug could pave 
the way to the development of innovative primary and secondary containers for the cost 
effective storage and transport of this new class of medicinal product. 
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hMSCs are currently considered  one of the most promising ‘living’ pharmaceutical 
ingredients, given their broad therapeutic potential and limited risk of immune rejection 
(Consentius et al., 2015). 
There is evidence that oxygen tension modulates the proliferation and differentiation 
potential of MSCs, although conflicting results can be found in the literature (Grayson, Zhao, 
Bunnell, & Ma, 2007a)(Holzwarth et al., 2010)(Wang, Fermor, Gimble, Awad, & Guilak, 
2005). The effect of oxygen, however, has never been studied in combination with 
temperature. 
A DoE based approach can be used as an investigation method to maximize the amount of 
information generated from experimental data and it is particularly useful for bioprocess 
systems as it is likely that process parameters interact (Montgomery, 2012). Moreover, DoE 
based models can be built and used as decision support tools, as previously shown in a 
number of industries (Montgomery, 2012). This would contribute to the development of the 
cell therapy product, in particular for autologous product, given the limited amount of ‘raw 
materials’ normally available for research and testing (Hourd et al., 2014). 
 
The aims of this research project are the following: 
 
 Investigate the combined effect of temperature, oxygen and storage duration for 
cartilage discs derived from hMSCs 
 Investigate the combined effect of temperature and oxygen on undifferentiated 
hMSCs 
 Demonstrate that statistical DoE can be successfully used as an investigational tool in 
cell therapy process development 
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 Develop predictive models that can be used in combination as a decision support tool 
for the development of robust storage and transportation solutions 
 
 
 
1.8  Thesis overview 
 
The subsequent thesis chapters are structured as follows:  
Chapter 2: Describes the investigation of the storage properties of cartilage discs following a 
shelf-life of 5 and 7 days. Eight storage conditions were simulated by combining two levels 
(high and low) for each of the three factors (temperature, oxygen and storage duration) 
according to a 23 full factorial design. Viability, metabolite concentrations in the spent 
medium and chondrogenic markers were evaluated as response variables.   
Chapter 3: Results described in Chapter 2 are further analysed using a system approach in 
order to highlight the effect of input parameters (temperature, oxygen and storage duration) 
on the response variables. The validity of the DoE based predictive models was assessed. 
Two case studies are also included, showcasing how the predictive models can be used as a 
decision support tool in the development of a storage and transportation solution for a cell 
therapy product.  
Chapter 4: Describes the investigation of storage properties for undifferentiated hMSCs. Four 
storage conditions were simulated by combining two levels (high and low) for each of the 
two factors (temperature and oxygen) according to a 22 full factorial design. Metabolite 
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concentrations in the spent medium and the three differentiation lineages characteristic of 
hMSCs were evaluated as response models. 
Chapter 5: Summarizes results, outlines challenges and provides suggestions for future work. 
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Chapter 2  
 
Investigating storage properties of scaffold 
free bone marrow derived cartilage discs 
 
 
 
 
 
 
 
Introduction 
 
 
Cell therapies have the potential to treat a variety of unmet clinical needs (Kefalas, 2015; 
Trounson & DeWitt, 2016). Compared to traditional pharmaceutical products, cell based 
medicinal products are more complex and product characterization as well as manufacturing 
is very challenging (Kirouac & Zandstra, 2008; Salmikangas et al., 2015). In order to reach 
their full clinical potential, these cell-based medicinal products need to be delivered to the 
hospital preserving their biological properties. Storage and transportation to clinical site can 
be considered as the last manufacturing steps and they normally rely on passive containers 
which are designed to maintain and monitor the temperature within a set range during 
shipment (PDA technical report).  As described in chapter 1, current storage and 
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transportation methods include controlled room temperature (CRT), hypothermic storage (2-8 
°C ) and cryopreservation (-80 °C, -196 °C). When cells are not cryopreserved and they are 
stored at CRT or hypothermic temperature, they will continue to metabolize glucose and 
glutamine to produce energy (Rafalski, Mancini, & Brunet, 2012). Waste products of these 
metabolic processes are lactate and ammonia (NH3). These have known detrimental effects 
on biological properties of human mesenchymal stem cells (hMSCs) (Schop et al., 2009). To 
date, the effort of minimizing lactate and ammonia release has been focused on hMSCs 
growth and is normally achieved by media replenishment. While this is standard practice in a 
laboratory or production environment, it is not normally possible during storage and shipment 
of the product. It is, therefore, important to minimize the build-up of lactate and ammonia in 
the preservation medium containing the cell therapy product. Historically, temperature has 
been considered an important parameter which, if lowered, can reduce cellular metabolism 
(Reissis, Garcia-Gareta, Korda, Blunn, & Hua, 2013).  
In this study, oxygen tension has also been considered and in combination with temperature 
and storage length. The hypothesis is that oxygen can also modulate viability as well as waste 
product release, which will affect the biological properties of the product. Apart from 
viability, preservation of the biological function of the cell therapy product is important to 
prove safety and efficacy of the medicinal product ( Bravery et al., 2013; Martin et al., 2014).  
A potential cell therapy product for cartilage regeneration has been selected to test different 
combinations of temperature, oxygen and storage duration as shown in Fig.1.  
Hyaline articular cartilage is a specialized tissue which is characterized by low cell density, 
high matrix content, lack of vascularization and very limited repair capacity. Once damaged, 
progressive degradation can lead to disease such as osteoarthritis (OA) causing low-level 
inflammation and severe pain. Cell based therapies have been developed over the past 
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decades and are based on transplantation of ex-vivo expanded autologous chondrocytes 
harvested from a non-load bearing region of the same joint. The inability to expand a 
sufficient number of chondrocytes retaining their functional properties, limited clinical 
efficacy and high costs have led to investigations into alternatives. hMSCs, from bone 
marrow and adipose tissue, can differentiate into chondrocyte–like cells (Boeuf & Richter, 
2010; Dabiri, Heiner, & Falanga, 2013) and could potentially be used to regenerate damaged 
articular cartilage. If proven clinically successful, MSC-based therapies could also limit the 
need for total joint replacement (arthroplasty).  
Many cell culture methods have been developed to differentiate hMSCs towards 
chondrogenesis,  such as: monolayer culture, pellet culture, micromass culture and seeding on 
a biomaterial based scaffold (Djouad et al., 2007; Im, Jung, & Tae, 2006; Mackay et al., 
1998). It has been shown that transwell culture is the most efficient method to drive MSCs 
along the chondrogenic lineage since its cartilage-like matrix synthesis and deposition is 
greater than other established methods (Murdoch et al., 2007). Although cultured in static 
conditions, cells seeded on transwell inserts have access to nutrients and growth factors from 
above and below the permeable insert, which facilitates their chondrogenic differentiation 
into cartilage discs. In this study, it was assumed that the mechanism of action for this 
product would be engraftment and regeneration of cartilage. Ideally, an engineered tissue for 
cartilage regeneration should have high expression of the COL2A1 and ACAN genes, which 
encode for collagen type II 1 and aggrecan respectively, while the expression of fibroblast 
genes such as COL1A1, which encodes for collagen type I 1, should be minimal (Chen, 
Duan, Zhu, Xiong, & Wang, 2014). The expression of these three genes is used as part of the 
potency assay to confirm the predicted biological function of ChondroCelect , a market-
approved cell therapy product for cartilage regeneration ( Bravery et al., 2013). 
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Gene expression was therefore considered a potential potency assay, linked to the biological 
property of the tissue.  
Four tissue culture incubators were used to reproduce the storage conditions as shown in Fig. 
2.1 and to investigate the storage properties of the scaffold free bone marrow derived 
cartilage discs. This method is preferred to a passive container based simulation given the 
inability of the latter to control both temperature and oxygen within the selected ranges. For 
temperature, the 26-37 °C range was selected for study. Although currently not very 
common, this temperature range is closer to physiological conditions and, if proven 
successful, could contribute to the preservation of the biological function. Oxygen tension 
range was selected to be between 20 % (ambient) and 3 %, which is the range of oxygen 
tension (estimated to be between 1 and 6 %) experienced by articular cartilage in the deep 
zone (Gibson, Milner, White, Fairfax, & Wilkins, 2008). As most commercially available cell 
based products do not have a shelf life longer than 6 days when stored in hypothermic 
conditions (Swioklo et al. 2016), 7 days was chosen as the storage length limit.   
 
Figure 2.2 Multifactorial space under investigation. Eight storage conditions were defined by 
combining two levels (high and low) for the three factors: temperature, oxygen and storage 
duration. 
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2.1 Materials and methods 
 
2.1.1 Human Bone Marrow derived MSCs culture  
 
Human bone marrow derived MSCs (hMSCs) were isolated from human bone marrow 
mononuclear cells extracted from the posterior iliac crest of three healthy young Caucasian 
donors (Lonza Biosciences, Berkshire, UK) by adherence for 24 hours to 75 cm2 tissue 
culture flasks (Corning) and were expanded in monolayer culture with mesenchymal stem 
cell growth medium (MSCGM BulletKit, Lonza) supplemented with 5 ng/ml fibroblast 
growth factor-2 (R&D Systems, Abingdon, UK). Cultures were maintained in a humid 
atmosphere of 5 % CO2 / 95% air at 37 °C.  Once cells reached confluence, they were washed 
with Ca2+ and Mg2+ free phosphate buffered saline (PBS, Sigma) and then incubated at 37 C 
5% CO2 with 2 ml Trypsin/EDTA (Sigma) for enzymatic harvesting. Cells were passaged at 
a split ratio of 1:3. Isolated MSCs were characterized by flow cytometry on a FACSanto II 
system (Becton Dickinson, Oxford, UK) using  a human MSC Phenotyping Kit (Miltenyi 
Biotec, Bisley, UK) with positive staining for CD73, CD90 , and CD105 and negative 
staining for CD14, CD20, CD34, and CD45 according to ISCT guidelines (Dominici et al., 
2006). Isolated MSCs from one additional healthy donor were also purchased from Lonza 
Biosciences. Donors details are provided in Appendix I. Experiments were performed using 
hMSCs between passages 4-5 (P4-P5). 
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2.1.2 Chondrogenic differentiation of hMSCs using the tranwell method 
 
hMSCs were expanded in 75 cm2 tissue culture flasks. Once the cells reached 80 % 
confluence, they were enzymatically detached by Trypsin/EDTA (Sigma) and centrifuged for 
5 minutes at 1200 rpm. Supernatant was removed and the cell pellet was re-suspended in pre-
warmed PBS (Sigma). Washed hMSCs were finally re-suspended in chondrogenic medium 
(Table 2.1). 
Table 2.1 Chondrogenic medium composition.   
Reagent Supplier Function 
High Glucose (4.5 g/l) 
Dulbecco's Modified 
Eagle Medium 
(DMEM)  
with sodium pyruvate   
(Lonza 12-614) Enables cell growth and proliferation. (Z. Yang & Xiong, 
2012) 
Transforming Growth 
Factor (TGF) TGF-3 
(10 ng/ml) 
PeproTech, London, 
UK 
Stimulates hMSCs to produce extracellular matrix rich in 
cartilage specific collagen type II and aggrecan (DeLise, 
Fischer, & Tuan, 2000) 
Dexamethasone (100 
nM) 
Sigma-Aldrich, 
Poole, UK 
Enhances chondrogenesis of MSCs induced by TGF-3 
(Shintani & Hunziker, 2011) 
Ascorbic acid -2-
phosphate (50 g/ml) 
Sigma-Aldrich, 
Poole, UK 
Stimulates secretion of collagen and glycosaminoglycan 
(Eslaminejad, Fani, & Shahhoseini, 2013) 
Proline (40 g/ml) Sigma-Aldrich, 
Poole, UK 
Essential amino acid which supports cells proliferation 
(Li, Sattler, & Pitot, 1995) 
100X Insulin-
Transferrin-Selenium 
(ITS+L) premix 
ITS+L; BD 
Biosciences, 
Oxford, UK 
ITS contains insulin, human transferrin and selenous acid. 
They stimulate cell proliferation under serum-reduced or 
serum free conditions (Kisiday, Kurz, DiMicco, & 
Grodzinsky, 2005) 
L-Glutamine Sigma-Aldrich, 
Poole, UK 
Essential amino acid required for cell growth (Z. Yang & 
Xiong, 2012). 
Penicillin/streptomycin 
(100 U/ml penicillin; 
100 μg/ml 
streptomycin mix)  
Sigma-Aldrich, 
Poole, UK 
Used in culture media to mitigate risk of bacterial and 
fungal infections. 
 
Four x 105  hMSCs in 100 l chondrogenic medium were seeded onto a 6.5 mm diameter, 0.4 
m pore size polycarbonate transwell insert (Merck Millipore, Watford, UK) and centrifuged 
in a 24-well plate (200g, 5 minutes). Five hundred l of chondrogenic medium were added to 
the lower well as described by Tew et al. (Tew, Murdoch, Rauchenberg, & Hardingham, 
2008). The chondrogenic medium was replaced every 3 days up to 14 days. The consistency 
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of this chondrogenic differentiation protocol has been previously demonstrated by Murdoch 
et al. (Murdoch et al., 2007). However, it has been confirmed internally to ensure a consistent 
baseline of chondrogenic markers in the construct before performing storage experiments. 
This construct is referred to as scaffold-free bone marrow derived cartilage disc, henceforth 
cartilage disc.  
 
2.1.3 Alamar blue assay for scaffold-free bone marrow derived cartilage 
disc 
 
Metabolic assays such as Alamar blue, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide), MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfonyl)-2H- tetrazolium) and water-soluble tetrazolium salt (WST-1) (4-(3-(4-Iodophenyl)-
2-(4-nitrophenyl)2H-5-tetrazolio)-1,3-benzene disulfonate) are commonly used to indirectly 
measure the viability of cells . MTT values have been found to closely correlate those from 
Alamar blue (Ng, Leong, & Hutmacher, 2005). The Alamar blue assay (ThermoFisher 
Scientific) was used to indirectly measure viability of cartilage discs. The assay is based on a 
redox reagent (resazurin) that fluoresces in response to the chemical reductions which occur 
during cellular metabolism and therefore provides an indirect measure of viable cell number 
(Rampersad, 2012). Resazurin is taken up by the cells where it is reduced to resorufin and 
then secreted into the medium, which results in a visible colour change from blue to pink and 
a fluorescent signal that can be measured (Back, Khan, Gan, Rosenberg, & Volpe, 1999). The 
assay can detect as few as 50 cells (ThermoFisher; 
https://www.thermofisher.com/uk/en/home/references/ protocols/cell-and-tissue-
analysis/cell-profilteration-assay-protocols/cell-viability-with-Alamarblue.html). Given the 
considerable overlap of the absorbance spectra for oxidised and reduced forms of the reagent, 
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fluorescence measurements are preferred (Back et al., 1999). The assay was performed 
according to the manufacturer’s instructions. However, it has been validated to confirm its 
robustness for use with the cartilage discs. To this end, four scaffold-free bone marrow 
derived cartilage discs were prepared as described in 3.1.2. These were cut into 4 quarters 
using a scalpel blade and 3 quarters were used for the Alamar blue assay (Fig. 2.2). Samples 
were placed in a 96-well plate in triplicates before adding 100 l of chondrogenic medium 
and 10 l of pre-warmed Alamar blue reagent. Negative controls were included by adding 10 
l of pre-warmed Alamar blue reagent to 100 l of chondrogenic medium not containing 
cells. A mix of chondrogenic medium and 10 % Alamar blue reagent was autoclaved in order 
to reduce the resazurin contained in the Alamar blue reagent. This represents the upper limit 
of resazurin reduction and was used as positive control. The plate was incubated at 37 °C and 
fluorescence values were measured every hour for 8 hours using a fluorescence 
spectrophotometer (Perkin Elmer LS50B) (excitation 560 nm, emission 590 nm). This 
experiment was also used to confirm the incubation time (4 h) suggested by the manufacturer 
as this is cell-depended.  
 
55 
 
 
Figure 2.2 Schematic view of the Alamar blue assay cartilage disc. Three technical replicates are 
sampled by cutting the discs into four quarters with a scapel blade. Three of the quarters are 
used for the Alamar blue assay. Each quarter was added to 100 l chondrogenic medium and 10 
l Alamar blue reagent in a 96 well plate. Negative controls containing no cells were included. A 
mix of chondrogenic medium + 10% Aamar blue reagent was autoclaved and used as positive 
control as resazurin contained in the Alamar blue is completely reduced to resorufin. The plate 
was incubated at 37 ⁰C and Alamar blue fluorescence values were measured every hour for 
eight hours.  (Ex l= excitation wavelength; Em l= emission wavelength)  
 
 
 
 
 
2.1.4 Quantitative viability indicator  
 
As it was not possible to isolate the cells from the scaffold-free bone marrow derived 
cartilage disc and create a standard curve for the Alamar blue assay, a quantitative viability 
indicator was defined as follows: 
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𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑖𝑛𝑑𝑖𝑐𝑎𝑡𝑜𝑟 =
[𝐴𝑙𝑎𝑚𝑎𝑟 𝑏𝑙𝑢𝑒 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑣𝑎𝑙𝑢𝑒]
𝐷𝑁𝐴 (𝑛𝑔)
 
 
Alamar blue fluorescence values were normalized by the amount of DNA contained in the 
sample, which was measured via the Picogreen Assay (Life Technologies). This assay has 
higher sensitivity than alternative options (such as Hoechst dyes or propidium iodide) and can 
detect as little as 25 pg/ml of double strand DNA (dsDNA) 
(ThermoFisher;https://www.thermofisher.com/order/catalog/product/P11496 ). As Picogreen 
dye cannot penetrate cell membranes, samples need to be lysed first to ensure that DNA is 
released. Extra cellular matrix proteins do not interfere with Picogreen fluorescence signals 
(Dragan et al., 2010). Scaffold-free bone marrow derived cartilage discs were cut into 4 
quarters using a scalpel blade; 3 quarters were used for the Alamar blue and Picogreen assay 
(n=3) while 1 quarter was used for gene expression analysis (Fig 2.3). Samples were placed 
in a 96-well plate in triplicates before adding 100 l of chondrogenic medium and 10 l of 
pre-warmed Alamar blue reagent. Negative controls were also included by adding 10 l of 
pre-warmed Alamar blue reagent to 100 l of chondrogenic medium not containing cells. 
Fluorescence values were detected after 4 hours incubation at 37 °C using a fluorescence 
spectrophotometer (Perkin Elmer LS50B) (excitation 560 nm, emission 590 nm), 
according to manufacturer instructions. The incubation time had been verified as described in 
3.1.4 to confirm that after 4 hours the fluorescence signal is still in its linear phase and does 
not reach a plateau. To compensate for phenol red fluorescence, negative controls were 
subtracted to fluorescence values for each sample. After Alamar blue fluorescence values 
have been measured, samples were then washed in PBS and transferred to 1.5 ml tubes 
(Eppendorfs). One ml of 1X Cyquant (ThermoFisher Scientific) lysis buffer was added to 
each sample before storage at – 80 °C. On the day the Picogreen assay was to be performed, 
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samples were thawed and homogenized with pestles. Three technical replicates were 
performed for each DNA sample. For each replicate, 100 l of DNA containing sample was 
added to 100 l of Picogreen Reagent (diluted 1:200). A standard curve was created using 
DNA (2 g/ml) provided in the kit. The plate was then covered with foil and incubated for 
5 minutes at room temperature before reading fluorescence values using a spectrophotometer 
(excitation 480 nm, emission 520 nm). DNA amount per sample was calculated using 
theDNA standard curve. 
Figure 2.3. Schematic view of the quantitative viability indicator assay for scaffold-free bone 
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marrow derived cartilage discs. The assay is based on Alamar blue and Picogreen assays 
performed on the same sample. Each disc was cut into four quarters; three were used for 
Alamar blue and Picogreen assays and one was used for gene expression analysis. For each disc, 
three technical replicates were available (samples A, B, and C). Alamar blue fluorescence values 
were measured for each sample (Ex 560 nm, Em nm For each sample, the amount of 
DNA was then quantified by Picogreen assay. Alamar blue fluorescence values were normalized 
by the amount of DNA per each sample. The resulting values were defined as viability indicator. 
(Ex = excitation wavelength; Em = emission wavelength). 
 
 
 
 
 
2.1.5 Storage of cartilage discs 
 
Nine scaffold-free bone marrow derived cartilage discs were prepared as described in 3.1.2. 
The storage experiment started on the day these discs were available (Fig.2.4). Each disc was 
transferred to a new 24-well plate in its transwell insert. Fresh chondrogenic medium (2.4 ml) 
was added to each disc before the storage period. Plates were then placed in tissue culture 
incubators according to the storage conditions shown in Table 2.2. One disc was used as 
control (storage start-day 0). After storage, discs were harvested, washed in pre-warmed PBS 
and spent medium aspirated for further analysis as described in 3.1.6. For each disc, the total 
amount of DNA contained in the three quarters of the disc used for the quantitative viability 
indicator (2.1.4) was used to identify potential significant differences in the cell number 
between different discs used for the storage experiment. The experiment was performed for 
three healthy donors.  
 
Table 2.2 Storage conditions. Two levels (low and high) were selected for each of the three 
parameters under investigation: Temperature, oxygen partial pressure (pO2) and storage 
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duration. Eight combinations were defined by combining low (-) and high (+) values for the 
three parameters.  
Run # Pattern Temperature 
(°C) 
pO2 (%) Storage duration 
(days) 
1 + + - 37 20 5 
2 + - - 37 3 5 
3 - + - 26 20 5 
4 - - - 26 3 5 
5 + + + 37 20 7 
6 + - + 37 3 7 
7 - + + 26 20 7 
8 -  - + 26 3 7 
 
 
 
 
Figure 2.4 Schematic view of the storage experiment of scaffold-free bone marrow derived 
cartilage discs.  
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2.1.6 Spent medium analysis 
 
To quantify the metabolite concentration of scaffold free bone marrow derived discs after 
storage, spent medium was aseptically removed from the wells after the storage period and 
stored at -80 °C in 1.5 ml tubes (Eppendorfs). Fresh medium samples were also included as 
control. Stored samples were thawed and run on the Bioprofile FLEX bioanalyzer (Nova 
Biomedical) for measurement of glucose [g/l], lactate [g/l], glutamine [mM] and ammonium 
[mM]. The bioanalyzer consists of biosensors which, once in contact with glucose, lactate, 
glutamine and ammonium, will convert the concentration into an electrical signal. The 
machine is automatically calibrated every hour. For each storage condition and each disc, 
only 2 ml of spent medium were available. As each measurement requires 1 ml of spent 
medium, only two technical repeats were possible for each storage condition.  
 
2.1.7 Extraction of total RNA 
 
RNA was extracted using the Trizol/chloroform method.  Molecular grinding resin (G-
Biosciences, St. Louis, USA) was added to each tube containing the samples, which were re-
suspended in 250 l Trizol (LifeTechnologies, USA). The samples were homogenized with 
pestles and incubated at room temperature for 5 minutes. Phase separation was achieved by 
addition of 50 l of chloroform (Fisher Scientific), vigorous shaking of the tubes, incubation 
at room temperature for 2 minutes and centrifugation at 4 °C at 13000 rpm for 15 minutes. 
The aqueous phase was transferred to a fresh 1.5 ml tube and mixed with 125 l of 
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isopropanol (LifeTechnologies, USA) to precipitate the RNA.  The tubes were then vortexed, 
incubated at room temperature for 10 minutes and centrifuged at 4 °C at 13000 rpm for 10 
minutes. The RNA pellets in each tube were washed in a 250 l solution of 75 % ethanol-25 
% DEPC-treated water (Invitrogen). The tubes were centrifuged at 4 °C at 13000 rpm for 5 
minutes. The ethanol was discarded and the pellets left to air dry for 10 minutes before being 
re-suspended in 30 l of DEPC-treated water. The RNA was quantified using a Nanodrop 
1000 spectrophotometer and the RNA samples were stored at – 80 °C.  
 
 
2.1.8 Gene Expression analysis  
 2.1.8.1 cDNA synthesis 
cDNA was synthesised from 1 g of RNA. RNase-free pipettes and tubes were used 
throughout to ensure that the RNA did not degrade. To remove genomic DNA (gDNA) 
contamination, 4 μl of 250 ng/μl RNA was incubated at 37 °C for 30 minutes with 1 μl of 
Turbo DNase (2 units; Ambion), 1 μl of DNase buffer (10X; Ambion) and 4 μl of DEPC-
treated water (Invitrogen). DNase was inactivated by adding 1.8 ml of 100mM 
Ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich, Poole, UK) and then incubating at 
75 °C for 10 minutes.  The DNase treated RNA was incubated with 1µl random primers (50 
ng/μl), 1µl of 10mM dNTP mix, 2 µl DEPC water for 5 mins at 65°C (all from Invitrogen). 
Reaction tubes containing RNA samples were then placed on ice for 1 minute. A reaction mix 
of 4 ml of 5X RT Buffer , 4 l of 25mM MgCl2 (Applied Biosystems, ABI, Life 
Technologies), 2 l of 10mM DTT and 1 l  RNaseOUT inhibitor (Invitrogen) was added to 
each tube and reactions were incubated at 25 °C for 1 minute.  SuperScript II RT enzyme 
(200 U/μl; Invitrogen) was diluted four times using DEPC water and 1 μl (50 U) of this was 
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added to the reaction and mixed by pipetting. The reverse transcriptase (RT) reaction was 
carried out by incubating at 25 °C for 10 minutes, 42 °C for 50 minutes and 70 °C for 15 
minutes. cDNA samples were then stored at -20 °C. 
 
2.1.8.2 Quantitative real-time PCR 
 
Taqman assays used primers and probes commercially available (IDT, Glasgow, UK) to 
analyse gene expression changes in a panel of selected genes (Table 2.3). Two and a half 
microliters of 1:20 diluted cDNA were added to 7.5 l of assay master mix in wells of a 
MicroAmpr fast optical 96 well reaction plate (ABI, Life Technologies). The components of 
the master mix are shown in Table 2.4. Three technical repeats were performed for each 
sample. Quantitative real time PCR was performed using an ABI PRISM 7900HT Sequence 
Detection System, setting the following cycle conditions: 40 cycles of 95 ̊C for 15 seconds 
and 60 ̊C for 20 seconds. The gene expression was analysed using the comparative cycle 
threshold (Ct) method using SDS 2.3 software (Applied Biosystems). For each gene, Ct 
values were calculated using the delta Ct method and relative to the average of the 
housekeeping genes 18S, HPRT1 and GAPDH (2− (𝐶𝑡 𝑡𝑒𝑠𝑡 𝑔𝑒𝑛𝑒−𝐶𝑡 𝑚𝑒𝑎𝑛 𝑜𝑓 ℎ𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑒𝑟𝑠)).  
 
Table 2.3 Primers used for quantitative real time PCR 
Gene Primer type Sequence (5’-3’) 
GAPDH Forward  ACATCGCTCAGACACCATG 
Reverse  TGTAGTTGAGGTCAATGAAGGG 
Probe  AAGGTCGGAGTCAACGGATTTGGTC 
HPRT1 Forward  TGCTGAGGATTTGGAAAGGG 
Reverse  ACAGAGGGCTACAATGTGATG 
Probe  AGGACTGAACGTCTTGCTCGAGATG 
18s Forward  CGAATGGCTCATTAAATCAGTTATGG 
Reverse  TATTAGCTCTAGAATTACCACAGTTATCC 
Probe  TCCTTTGGTCGCTCGCTCCTCTCCC 
COL2A1 Forward  ACCTTCATGGCGTCCAAG 
Reverse  AACCAGATTGAGAGCATCCG 
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Probe  AGACCTGAAACTCTGCCACCCTG 
ACAN Forward  TGTGGGACTGAAGTTCTTGG 
Reverse  AGCGAGTTGTCATGGTCTG 
Probe  CTGGGTTTTCGTGACTCTGAGGGT 
COL1A1 Forward  CCCCTGGAAAGAATGGAGATG 
Reverse  TCCAAACCACTGAAACCTCTG 
Probe  TTCCGGGCA ATCCTCGAGCA 
 
 
 
Table 2.4: Reaction mix for TaqMan assays. TFU: TaqMan Fast Universal PCR Master Mix 
(Applied Biosystems). Primer probe mix contains forward primer, reverse primer and probe. 
Master mix for 18S  Master mix for HPRT1, GAPDH, COL2A1, 
ACAN, COL1A1 
TFU 5 μl 
Forward primer 0.2 μl 
Reverse primer 0.2 μl 
Probe 0.4 μl 
Water 2 μl 
TFU 5 μl 
Primer probe mix 1 μl 
Water 1.5 μl 
 
2.1.9 Statistical analysis  
 
As raw data were affected by donor to donor variability, different storage conditions were 
compared using the least-squares means (LS-means) method (Montgomery, 2012). LS-means 
were estimated from raw data for each response variable (Viability indicator, glucose, lactate, 
glutamine, ammonia, COL2A1, ACAN, COL1A1) using JMP SAS software 
(http://www.jmp.com/en_us/home.html). This method compensates for donor to donor 
variability by considering all storage conditions as part of three sets of data: donor #1, donor 
#2, donor #3 (Montgomery, 2012). Statistical significance was assessed by graphically 
comparing confidence intervals (95%) of the different storage conditions listed in Table 2.2. 
Non-overlapping confidence intervals indicate statistically different storage conditions. This 
identifies sets of storage conditions which are consistently different across all three donors. It 
also allows identification of overall statistical difference between the three donors.  
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2.2 Results  
 
2.2.1 Alamar blue assay for cartilage discs 
 
Murdoch et al. (Murdoch et al. 2007) demonstrated that hMSCs, when cultured in transwell 
insert with TGF-3 and dexamethasone, will proliferate mainly in the first 7 days and will 
then form a cartilage matrix that stains strongly and uniformly with Safranin O, which stains 
glycosaminoglycans (Kiviranta, Jurvelin, Säämänen, & Helminen, 1985). Compared to the 
well-established pellet culture protocols, it was possible to obtain uniform cartilage discs 20-
fold bigger in wet mass with the same amount of cells and identical chondrogenic medium. 
They also showed increased collagen II and aggrecan expression. 
In this study hMSCs were differentiated via the transwell insert method in the presence of 
chondrogenic medium (Fig. 2.5) and formed cartilage discs. These were used as a cell 
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therapy model for storage experiments. In order to measure the viability of the discs 
following storage experiments, the Alamar blue assay was preliminarily tested on four discs. 
Results are shown in Fig. 2.6.  
 
 
Figure 2.5 Chondrogenic differentiation of hMSCs into cartilage discs. Cells were cultured for 14 
days in a transwell with chondrogenic medium (Table 1) forming a 7 mm diameter disc which has 
been used as cell therapy product model for subsequent experiments. Scale bar= 500 m). 
 
Alamar blue fluorescence values consistently increased for all 4 discs over 8 hour incubation 
time and between the negative control and positive control values. These results also confirm 
that after 4 h incubation (as per manufacturer’s instruction), the Alamar blue curve is still in 
its linear phase and has not reached its plateau. A 4 hour incubation can therefore be used to 
measure the viability via the Alamar blue assay for this specific cell therapy product. For 
each time point, Alamar blue fluorescence values for the four discs did not show a significant 
spread between discs demonstrating the reproducibility of this assay.  
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Fig 2.6 Alamar blue fluorescence (Relative fluorescence units, RFU) of four cartilage discs 
during 8 h incubation at 37 °C. Each disc was prepared as described in 3.1.2 using hMSCs 
isolated from 1 healthy donor. For each time point, results are represented as mean ± standard 
deviation for three technical replicates. These were sampled by cutting each disc into four 
quarters and using three for the Alamar blue assay. Negative control samples were included 
(chondrogenic medium plus Alamar blue reagent only). Positive control was created by 
preliminary autoclaving chondrogenic medium and Alamar blue reagent. Resazurin contained 
in the Alamar blue reagent is reduced and changes color from blue to pink.  
 
 
 
 
 
2.2.2 Post storage viability of scaffold-free bone marrow derived cartilage 
discs 
 
In order to investigate the stability of the cell product post storage, eight scaffold-free bone 
marrow derived cartilage discs were prepared. 
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Discs were stored in 4 tissue culture incubators simulating 8 different storage conditions 
(Table 2.2). Discs were then characterized in terms of viability, spent medium metabolites 
and gene expression (Fig 2.4). The experiment was undertaken for the three healthy young 
Caucasian donors.  
The Alamar blue and Picogreen assay were used to indirectly measure cell viability of the 
cartilage discs after storage, as described in 3.1.4. Viability indicator values relative to day 0 
(storage start) for each storage condition and for the three healthy donors are shown in Fig. 
2.7. For all three donors, storage at 26 °C led to a better viability than storage at 37 °C after 
both 5 and 7 days. After 5 days at 26 °C, viability is even higher than at day 0 (storage start) 
for both oxygen levels (20 % and 3 %). This could be due to the proliferation of cells over 5 
day storage. A similar trend can be seen after 7 day storage. For all storage conditions, 
viability decreased at day 7 reaching the lowest value (57.7%) at 37 °C and 20% O2 for donor 
#2. Oxygen tension did not have a large effect on modulating viability post-storage, although 
differences in viability indicator can be noticed for donor #3 both at day 5 and day 7 when 
stored at 26 °C.  
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Figure 2.7 Post-storage viability indicator of cartilage discs measured via Alamar blue and 
Picogreen assays. Discs were prepared using bone marrow derived hMSCs isolated from three 
healthy donors. Discs where exposed to storage conditions listed in Table 2.2. For each disc, 
Alamar blue fluorescence was measured by cutting the disc into four quarters (three quarters 
were used for Alamar Blue and Picogreen Assay). For each quarter, Alamar blue fluorescence 
was normalized by the amount of DNA measured via Picogreen assay. This was defined as the 
viability indicator. Viability indicator values for all storage conditions and all three donors are 
plotted relative to a disc not exposed to storage conditions (storage start,day 0). Values are 
plotted as mean and standard error of the mean (n=3). (37 C=37 °C, O2=pO2 oxygen tension, 
D5= day 5, D7= day 7). 
 
 
Figure 2.8 shows that although the estimated least square means (LS-means) of viability 
indicator for each storage condition are different between donors, these are not statistically 
different. It is possible to notice a consistent trend in the viability indicator for all three 
donors, with lower values corresponding to higher temperature and longer storage period. 
Viability following 5 day storage at 26 ⁰C and 3 % O2 was statistically different across all 
three donors than viability following 7 day storage at 37 ⁰C and 20 % oxygen and 37 ⁰ C and 
3 % oxygen.  
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The amount of DNA per disc was also analysed to detect possible variations that could affect 
the above mentioned considerations on variability indicators. For each disc, the total amount 
of DNA was calculated by adding the DNA contained in the three quarters used to normalize 
the Alamar blue fluorescence values. Fig. 2.9 shows that for all three donors, the total amount 
of DNA contained in each disc was within an average value and two standard deviations 
(mean ± SD, upper control limit and lower control limit).  
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Figure 2.8 Least square means for viability indicator for cartilage discs following storage 
conditions listed in table 2 for donor 1 (A), 2 (B) and 3(C) respectively. Least square means (LS-
means) were estimated using JMP SAS software.Viability indicator raw data used to estimate 
the LS-means were expressed as % relative to untreated samples which were not exposed to any 
storage condition.  Storage conditions were defined by combining high (+) and low(-) levels of 
the three parameters under investigation: temperature (37 -26 ̊C), oxygen (3-20 % O2)and 
storage duration (5-7 days). This method allows to compare by compensating for donor to 
donor variability. Left (A,B,C), least square means for viabiliy indicator (%) for each storage 
condition. Right (A,B,C),  least square means for each donor calculated across all storage 
conditions.  Error bars represent 95% CI. Confidence intervals that do not overlap represent 
storage conditions which were consistently different across the three donors. Statistically 
different storage conditions or donors can be identified by non-overlapping CIs. 
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Figure 2.9 Control charts for total DNA (ng) contained in three quarters of scaffold-free bone 
marrow derived cartilage disc measured via Picogreen assay. Each control chart (A, B and C) 
shows the average amount of DNA (Avg) for the three quarters for all discs used in the storage 
experiment for donor 1, 2 and 3 respectively. For each donor, day 0 corresponds to the disc used 
as control (storage start). Avg (green line) is the center line. Upper control limit (UCL) and 
lower control limit (LCL) represent +3 SD and – 3 SD respectively. All points are between the 
control limits. 
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It is possible that differences in the amount of DNA are due to variations in cutting the discs 
into quarters. Moreover, even if hMSCs are likely to distribute evenly on the surface of the 
transwell insert during seeding, heterogenicity of cell population might result in uneven 
proliferation within the transwell. This might lead to areas of the disc that are densely 
populated, explaining the small difference in DNA amount per disc. Discs from donor #2 
were visibly thinner than discs from donor #1 and #3 and this is confirmed by the lower 
average amount of DNA in discs from donor#2 (825.35 ng) compared to donor#1 (3438.57 
ng) and donor#3 (3220.43 ng). The reduced matrix formation might be explained by the 
limited proliferation of the cells in the transwell insert which was detected by measuring the 
amount of DNA (Fig. 2.9).  
 
2.2.2 Post storage metabolites concentration 
 
Glucose is the primary source of energy for cells. It can be metabolized to produce adenosine 
triphosphate (ATP) both in the presence of oxygen (aerobically) and in its absence 
(anaerobically). These reactions occur in the presence of temperature-dependent enzymes. 
Temperatures below 37 °C will lead to a slower reaction rate while higher temperature will 
cause enzyme denaturation (Berg, Tymoczko, & Stryer, 2012). The anaerobic pathway is 
coupled with the production of lactate. Accumulation of lactate also causes a reduction in 
intracellular pH, which can have detrimental effects on the viability of the cells (Schop et al., 
2009). Glutamine is a non essential amino acid which is hydrolysed by glutaminase yielding 
glutamate and ammonia as waste products. In addition to glucose, glutamine can also be used 
to generate cellular energy. Spent medium was aseptically isolated after 5 and 7 days of 
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storage and the concentration of glucose, lactate, glutamine and ammonia were measured. 
This was undertaken for all three donors.  
2.2.2.1 Glucose and lactate  
 
It was possible to determine which storage condition led to the lowest amount of glucose in 
the spent medium (Fig 2.10). 
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Figure 2.10 Post-storage glucose concentrations (g/l) in spent medium. Scaffold-free bone 
marrow derived cartilage discs were prepared using bone marrow hMSCs isolated from three 
healthy donors. Discs were exposed to storage conditions listed in Table 2.2. Dotted line 
represents initial glucose concentration in fresh medium (i.c.) (4.5 g/l). Each measurement 
requires 1 ml of spent medium. As only 2 ml of spent medium were available for each storage 
condition, two technical replicates only were possible. Values are plotted as mean and standard 
error of the mean (n=2). (37 C=37 °C, O2=pO2 oxygen tension, D5= day 5, D7= day 7). 
 
 
Five day storage at 26 °C and 20 % oxygen resulted in 34 % less glucose metabolized 
compared to discs stored at 37 °C and 20 % oxygen. Lower oxygen tension less markedly 
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affected the amount of glucose metabolized. At 37 °C, it decreased by 2 % at day 5 and 1.5 % 
at day 7. It can be noticed that at 26 °C, glucose consumption increased at 3% oxygen tension 
by 3.2 % both at day 5 and day 7.  Discs from donor #2 metabolized less glucose in all 
storage conditions and this is consistent with the reduced number of cells per disc described 
in 3.2.1. Figure 2.11 shows a consistent trend in consumption of glucose for all three donors. 
Unlike viability indicator where LS-means were different despite the consistent trend, 
glucose consumption was very similar for donor #1 and #3.  
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Figure 2.11 Least square means for glucose for scaffold-free bone marrow derived cartilage 
discs following storage conditions listed in table 2 for donor 1 (A), 2 (B) and 3(C) respectively. 
Least square means (LS-means) were estimated using JMP SAS software. Storage conditions 
were defined by combining high (+) and low(-) levels of the three parameters under 
investigation: temperature (37 -26 ̊C), oxygen (3-20 % O2)and storage duration (5-7 days). This 
method allows to compare by compensating for donor to donor variability. Left (A,B,C), least 
square means for glucose for each storage condition. Right (A,B,C),  least square means for each 
donor calculated across all storage conditions.  Error bars represent 95% CI. Confidence 
intervals that do not overlap represent storage conditions which were consistently different 
across the three donors. Statistically different storage conditions or donors can be identified by 
non-overlapping CIs.  
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Similarly to glucose, it was possible to determine which condition led to the minimum 
amount of lactate released by the discs during storage (Fig 2.12). For all the three donors, the 
highest amount of lactate was produced when the discs were stored at 37 °C as opposed to 26 
°C. This can be explained by the reduced metabolism of cells at 26 °C and it is consistent 
with the amount of glucose which was metabolised (Fig 2.10). Lactate production was 87 % 
higher at 37 °C compared to 26 °C after 5 days and 82 % after 7 days. While lower oxygen 
tension at 37 °C only led to a 1 % decrease in lactate release after 5 days, the effect was 
greater and resulted in a 4 % decrease after 7 day storage. 
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Figure 2.12 Post-storage lactate concentrations (g/l) in spent medium. Initial concentration is 0 
g/l. Scaffold-free bone marrow derived cartilage discs were prepared using bone marrow 
hMSCs isolated from three healthy donors. Discs were exposed to storage conditions listed in 
Table 2.2. Each measurement requires 1 ml of spent medium. As only 2 ml of spent medium 
were available for each storage condition, two technical replicates only were possible. Values are 
plotted as mean and standard error of the mean (n=2). (37 C=37 °C, O2=pO2 oxygen tension, 
D5= day 5, D7= day 7). 
 
As with glucose, it is apparent that when the discs were stored at 26 °C and 3 % oxygen the 
production of lactate (and the metabolism of glucose) increased compared to when stored at 
26 °C and 20 % oxygen. This effect tends to be greater after day 7 (43 % increase) than after 
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day 5 (33 % increase) day storage. Lactate release inversely matched glucose concentration 
with higher values for longer storage at higher temperature (Fig.2.12). 
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Figure 2.13 Least square means for lactate for scaffold-free bone marrow derived cartilage discs 
following storage conditions listed in table 2 for donor 1 (A), 2 (B) and 3(C) respectively. Least 
square means (LS-means) were estimated using JMP SAS software.  Storage conditions were 
defined by combining high (+) and low(-) levels of the three parameters under investigation: 
temperature (37 -26 ̊C), oxygen (3-20 % O2)and storage duration (5-7 days). This method allows 
to compare by compensating for donor to donor variability. Left (A,B,C), least square means 
for lactate (%) for each storage condition. Right (A,B,C),  least square means for each donor 
calculated across all storage conditions.  Error bars represent 95% CI. Confidence intervals 
that do not overlap represent storage conditions which were consistently different across the 
three donors. Statistically different storage conditions or donors can be identified by non-
overlapping CIs. 
 
 
Lactate release from donor #2 was statistically different than donor #1 and #3 (Fig. 2.13). 
Discs prepared using hMSCs from these two donors showed a very similar metabolism 
during storage both in terms of glucose consumption and lactate release, suggesting a strong 
effect of cell number on tissue metabolism rate.  
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2.2.2.2 Glutamine and ammonia 
 
Glutamine concentration (mM) in spent medium after 5 and 7 day storage was measured and 
the results are shown in Fig.2.14. 
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Figure 2.14 Post-storage glutamine concentrations (mM) in spent medium. Scaffold-free bone 
marrow derived cartilage discs were prepared using bone marrow hMSCs isolated from three 
healthy donors. Discs were exposed to storage conditions listed in Table 2.2. Dotted line 
represents initial glutamine concentration in fresh medium (i.c.) (2 mM). Each measurement 
requires 1 ml of spent medium. As only 2 ml of spent medium were available for each storage 
condition, two technical replicates only were possible. Values are plotted as mean and standard 
error of the mean (n=2). (37 C=37 °C, O2=pO2 oxygen tension, D5= day 5, D7= day 7). 
  
 
 
It was possible to notice that different temperature and oxygen tension levels can trigger 
different metabolic pathways. When stored at 37 °C, discs metabolise all glutamine available. 
At a lower temperature, glutamine metabolism was greatly reduced. This further decreased at 
lower oxygen tension level (3%). This suggests that storage at lower temperature and hypoxic 
condition also reduces glutamine metabolism. Glutamine concentration in the spent medium 
post-storage ranged from 1% of the initial glutamine concentration (2 mM) after 5 day 
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storage at 37 °C and 20 % oxygen to 76 % after 5 days storage at 26 °C and 3 % oxygen. All 
three donors consistently responded to changes in temperature and oxygen tension levels 
during storage (Fig. 2.15). Glutamine metabolism was lower for discs from donor #2, 
although this was not statistically significant. 
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Figure 2.15 Least square means for glutamine for scaffold-free bone marrow derived cartilage 
discs following storage conditions listed in table 2 for donor 1 (A), 2 (B) and 3(C) respectively. 
Least square means (LS-means) were estimated using JMP SAS software. Storage conditions 
were defined by combining high (+) and low(-) levels of the three parameters under 
investigation: temperature (37 -26 ̊C), oxygen (3-20 % O2)and storage duration (5-7 days). This 
method allows to compare by compensating for donor to donor variability. Left (A,B,C), least 
square means for glutamine for each storage condition. Right (A,B,C),  least square means for 
each donor calculated across all storage conditions.  Error bars represent 95% CI. Confidence 
intervals that do not overlap represent storage conditions which were consistently different 
across the three donors. Statistically different storage conditions or donors can be identified by 
non-overlapping CIs. 
 
Closely linked to glutamine metabolism, ammonia concentration in spent medium post-
storage was also measured in order to assess which storage conditions would be less 
detrimental for the cell based product. Results are shown in Fig. 2.16. 
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Figure 2.16 Post-storage NH3 concentrations (mM) in spent medium. Scaffold-free bone marrow 
derived cartilage discs were prepared using bone marrow hMSCs isolated from three healthy 
donors. Discs were exposed to storage conditions listed in Table 2.2. Initial NH3 concentration 
was 0 mM. Each measurement requires 1 ml of spent medium. As only 2 ml of spent medium 
were available for each storage condition, two technical replicates only were possible. Values are 
plotted as mean and standard error of the mean (n=2). (37 C=37 °C, O2=pO2 oxygen tension, 
D5= day 5, D7= day 7). 
 
 
Consistently with glutamine metabolism, lower temperature and oxygen levels led to a 
reduced amount of ammonia produced both after 5 and 7 days of storage. Ammonia 
concentration in spent medium was as high as 0.525 mM (n=3) after 5 days (37 °C and 20 % 
oxygen) and as low as 0.29 mM (n=3) at 5 days (26 °C and 3 % oxygen). Fig. 2.17 shows 
that the amount of NH3 released at 26 °C and 20 % oxygen is statistically different from the 
amount released when the discs where stored at 26 °C and 3 % Oxygen, both after 5 and 7 
days and for all three donors.  
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This suggests that both glucose and glutamine metabolism could be potentially modulated by 
physical parameters like temperature and oxygen tension in order to minimize detrimental 
effect of waste products, such as lactate and ammonia.  
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Figure 2.17  Least square means for NH3 for scaffold-free bone marrow derived cartilage discs 
following storage conditions listed in table 2 for donor 1 (A), 2 (B) and 3(C) respectively. Least 
square means (LS-means) were estimated using JMP SAS software. Storage conditions were 
defined by combining high (+) and low(-) levels of the three parameters under investigation: 
temperature (37 -26 ̊C), oxygen (3-20 % O2)and storage duration (5-7 days). This method allows 
to compare by compensating for donor to donor variability. Left (A,B,C), least square means 
for viabiliy indicator (%) for each storage condition. Right (A,B,C),  least square means for each 
donor calculated across all storage conditions.  Error bars represent 95% CI. Confidence 
intervals that do not overlap represent storage conditions which were consistently different 
across the three donors. Statistically different storage conditions or donors can be identified by 
non-overlapping CIs. 
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2.2.3 Post storage gene expression analysis  
 
In order to assess if gene expression would change in response to different storage conditions, 
(for example, changing temperature and oxygen tension level at which discs were stored) 
RNA was extracted from discs post-storage and variation in gene expression quantified using 
quantitative real-time PCR. COL2A1 expression, which encodes for collagen type II 1, in 
terms of fold change relative to day 0 (storage start) are shown in Fig 2.18. 
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Figure 2.18 Fold change in COL2A1 gene expression in response to storage. Scaffold-free bone 
marrow derived cartilage discs were prepared using bone marrow hMSCs isolated from three 
healthy donors. Discs were exposed to storage conditions listed in Table 2.2. Fold change values 
are relative to an unstored disc and plotted as mean and standard error of the mean for three 
technical replicates for each donor. (37 C=37 °C, O2=pO2 oxygen tension, D5= day 5, D7= day 
7). 
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COL2A1 was more abundantly expressed in discs from donor #1 compared to discs from 
donor #2 and #3. It is reasonable to assume that the chondrogenic stimulation induced by     
TGF-continued during the storage period for donor #1 , with  higher fold changes relative 
to day 0 (storage start) at 7 days. For both storage length (5 and 7 days), a similar trend can 
be observed where lower temperature and higher oxygen tension correspond to higher fold 
change relative to day 0 (storage start). The fact that higher oxygen tension leads to 
upregulation of COL2A1 could be linked to in-vivo cartilage homeostasis.  When stored at 
37 ̊C and 3% oxygen, which closely mimic the environment experienced by the hMSCs in-
vivo in absence of injuries (Zhou, Cui, & Urban, 2004), COL2A1 was under regulated in discs 
from all three donors both after 5 and 7 day storage. As shown in Fig.2.19, discs from the 3 
donors showed a consistent trend although COL2A1 was expressed less in discs from donor 
#2 and even less in discs from donor #3. The three patterns were not statistically different. 
Moreover, no statistically significant difference was found between all 8 storage conditions.  
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Figure 2.19 Least square means for COL2A1 fold change for scaffold-free bone marrow derived 
cartilage discs following storage conditions listed in table 2 for donor 1 (A), 2 (B) and 3(C) 
respectively. Least square means (LS-means) were estimated using JMP SAS software. Fold 
changes are relative to untreated samples which were not exposed to any storage condition.  
Storage conditions were defined by combining high (+) and low(-) levels of the three parameters 
under investigation: temperature (37 -26 ̊C), oxygen (3-20 % O2)and storage duration (5-7 
days). This method allows to compare by compensating for donor to donor variability. Left 
(A,B,C), least square means for COL2A1 fold change for each storage condition. Right (A,B,C),  
least square means for each donor calculated across all storage conditions.  Error bars 
represent 95% CI. Confidence intervals that do not overlap represent storage conditions which 
were consistently different across the three donors. Statistically different storage conditions or 
donors can be identified by non-overlapping CIs. 
 
Similarly to COL2A1, fold changes relative to day 0 (storage start)  for ACAN, which codes 
for the major proteoglycan in hyaline cartilage, were higher for donor #1 compared to donor 
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#2 or #3 (Fig. 2.20) and this can be linked to the different proliferation of cells in the 
transwell. It has been reported that, other than chondrogenic medium, high cell density is key 
in inducing chondrogenic differentiation (Murdoch et al., 2007). Differences in fold change 
can be noticed for different oxygen tensions only for storage at 37 ̊C. At this temperature, 
ACAN was more abundantly expressed at 20 % oxygen compared to discs stored at 3 % 
oxygen for donor #1 and #3 after 5 day storage. For these two donors, the trend can be also 
noticed after 7 day storage, although fold change values were smaller. When storage at 26 ̊C, 
oxygen tension only leads to an increased fold change after 7 day storage. Differences in 
COL2A1 fold change values were consistent to those found for ACAN and they are probably 
due to the different chondrogenic process taking place in the discs from different donors as 
result of inter donor variability rather than storage conditions.    
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Figure 2.20 Fold change in ACAN gene expression in response to storage. Scaffold-free bone 
marrow derived cartilage discs were prepared using bone marrow hMSCs isolated from three 
healthy donors. Discs were exposed to storage conditions listed in Table 2.2. Fold change values 
are relative to an unstored disc and plotted as mean and standard error of the mean for three 
technical replicates for each donor. (37 C=37 °C, O2=pO2 oxygen tension, D5= day 5, D7= day 
7). 
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Figure 2.21 shows that mean fold change values for donor #1 are statistically different than 
mean fold change values for donor #3. No significant differences were found between storage 
conditions.  
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Figure 2.21 Least square means for ACAN fold change for scaffold-free bone marrow derived 
cartilage discs following storage conditions listed in table 2 for donor 1 (A), 2 (B) and 3(C) 
respectively. Least square means (LS-means) were estimated using JMP SAS software. Fold 
changes are relative to untreated samples which were not exposed to any storage condition.   
Storage conditions were defined by combining high (+) and low(-) levels of the three parameters 
under investigation: temperature (37 -26 ̊C), oxygen (3-20 % O2)and storage duration (5-7 
days). This method allows to compare by compensating for donor to donor variability. Left 
(A,B,C), least square means for ACAN fold change for each storage condition. Right (A,B,C),  
least square means for each donor calculated across all storage conditions.  Error bars 
represent 95% CI. Confidence intervals that do not overlap represent storage conditions which 
were consistently different across the three donors. Statistically different storage conditions or 
donors can be identified by non-overlapping CIs. 
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The expression of COL1A1, which encodes for collagen type I 1, in response to different 
storage conditions was also analysed (Fig. 2.22). COL1A1 was also down regulated for donor 
#1 compared to the other donors. This can be explained by the lower proliferation of the cells 
in the transwell for donor #3 compared to donor #1 and #2. As higher cell density induce 
better chondrogenesis as confirmed by COL2A1 and ACAN expression, lower cell density, on 
the other hand, correlates to an increased expression of COL1A1. 
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Figure 2.22 Fold change in COL1A1 gene expression in response to storage. Scaffold-free bone 
marrow derived cartilage discs were prepared using bone marrow hMSCs isolated from three 
healthy donors. Discs were exposed to storage conditions listed in Table 2.2. Fold change values 
are relative to an unstored disc and plotted as mean and standard error of the mean for three 
technical replicates for each donor. (37 C=37 °C, O2=pO2 oxygen tension, D5= day 5, D7= day 
7).  
 
 
Discs from donor #3 which showed a lower COL2A1 and ACAN expression in all storage 
conditions, showed higher COL1A1 expression relative to day 0 (storage start). For this 
donor, lower temperature and higher oxygen tension lead to an increase in COL1A1 fold 
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change after 5 and, although less marked, after 7 day storage.  Figure 2.23 shows that a 
similar pattern can be noticed among the three donors but the mean values are statistically 
different. Three statistical differences can also be found between storage conditions for all the 
three donors; storage at 26 ̊ C 20% oxygen for 5 days was significantly different than storage 
at 37 ̊ C 20 % or 3 % oxygen for 7 days. COL1A1 fold changes were also statistically 
different between discs stored at 37 ̊ C and 3 % oxygen and discs stored at 26 ̊ C 20 % 
oxygen for 7 days. 
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Figure 2.23 Least square means for COL1A1 fold changes for scaffold-free bone marrow 
derived cartilage discs following storage conditions listed in table 2 for donor 1 (A), 2 (B) and 
3(C) respectively. Least square means (LS-means) were estimated using JMP SAS software. 
Fold changes are relative to untreated samples which were not exposed to any storage condition.  
Storage conditions were defined by combining high (+) and low(-) levels of the three parameters 
under investigation: temperature (37 -26 ̊C), oxygen (3-20 % O2)and storage duration (5-7 
days). This method allows to compare by compensating for donor to donor variability. Left 
(A,B,C), least square means for COL1A1 fold changes for each storage condition. Right (A,B,C),  
least square means for each donor calculated across all storage conditions.  Error bars 
represent 95% CI. Confidence intervals that do not overlap represent storage conditions which 
were consistently different across the three donors. Statistically different storage conditions or 
donors can be identified by non-overlapping CIs. 
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2.3 Brief summary of data described  
 
In this chapter, the storage of cartilage discs from three healthy donors has been studied. 
Table 2.5 summarizes the key findings. 
 
Table 2.5 Brief summary of key findings for the storage of cartilage discs in a controlled 
environment for 5 and 7 days.  
 Key finding 
Viability  Storage at 26 °C led to a better viability than storage at 37 °C both at 5 and 7 days. 
Oxygen did not have a large effect on modulate viability.  
Metabolites 
Glucose  Glucose concentration in spent medium increased as storage temperature decreased 
from 37 to 26 °C and less remarkably when oxygen tension increased from 3 to 20 
%.  
Lactate The highest amount of lactate was produced when the discs were stored at 37 °C, 
consistently with glucose metabolism. 
Glutamine Storage at lower temperature and hypoxic conditions reduced glutamine 
metabolism 
Ammonia Consistently with glutamine metabolism, lower temperature and oxygen levels led 
to a reduced amount of ammonia produced both after 5 and 7 days of storage. 
Chodrogenic potential 
COL2A1 For both storage lengths, lower temperature and higher oxygen correspond to 
higher fold change relative to day 0 (storage start) 
ACAN Storage at higher temperature led to higher fold changes after 5 and 7 days.  ACAN 
was also upregulated for storage at higher oxygen but only at 37 °C. 
COL1A1 COL1A1 was upregulated for lower storage conditions at higher oxygen level both 
after 5 and 7 days. 
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2.4 Discussion 
 
 
The aim of this chapter was to investigate the storage properties of cartilage discs which have 
been used as engineered tissue model. These discs were prepared using the method developed 
by Murdoch et al. (2007). The effect of temperature was investigated in combination with 
oxygen tension over a period of 5 and 7 day storage. A number of research groups have 
investigated such parameters separately and mainly in order to optimize the expansion of 
cells in bioreactors for therapeutic purposes (Panchalingam et al., 2015; Schnitzler et al., 
2015). As cells are normally exposed to variation in temperature as well as oxygen tension 
when stored and transported to the clinical site, it is important to better understand their 
behaviour when exposed to different storage conditions. It can be noticed that preferential 
storage conditions in terms of viability, lactate and ammonia production, COL2A1 and ACAN 
production are the ones that led to upregulation of COL1A1, which should be minimal for 
cartilage-like tissue as collagen type I is abundant in bone ECM but nearly absent in hyaline 
cartilage (Brian Johnstone et al., 2013) 
Viability is considered the first step towards establishing the shelf life of the cell based 
product and is part of more complex, yet mandatory, stability studies (ICH Q5C, 
http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html). This is 
because it is not normally enough to prove that cells are alive but it is important that they 
maintain the relevant biological function once delivered to the patient. As described in 
chapter 1, the shelf life of commercially available products spans from a minimum of 18 h 
(Provenge, Dendreon) to a maximum of 15 days (Apligraf, Organogenesis). The former is a 
suspension of 50 x 106 autologous CD54+ cells activated with PAP-GM-CSF, while the latter 
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is an engineered tissue (75 mm in diameter and 0.75 mm thick) comprised of human 
fibroblasts and keratinocytes. This suggests that tissue engineered products might have longer 
shelf life compared to cells stored in suspension. The presence of extra cellular matrix might 
exert a protective effect to the cells enabling them to preserve their viability for longer. This 
hypothesis inspired the use of polymeric materials, like bioactive polymer fibrin (Janmey, 
Winer, & Weisel, 2009)and inert semi-permeable polymer alginate (Swioklo et al., 2016) to 
improve the preservation of cells during storage and transport. The approval of Holoclar 
(EPAR-EMA), which is the first advanced therapy medicinal product (ATMP) containing 
stem cells, demonstrate that cell type might, more than the formulation, dictate the extent of 
shelf life. This product, used for severe limbal stem cell deficiency due to chemical burn to 
the eye, consists of autologous human corneal epithelial cells on a fibril gel but its shelf life is 
limited to 36 hours. It should also be considered that many of the assays used for the viability 
assessment of tissues might hide cell loss as they discern dead cells on the basis of membrane 
integrity, which could be maintained due to the ECM even if the cells are actually dead or 
apoptotic. For this reason, Alamar blue assay has been increasingly being used to indirectly 
measure the viability of cells, aggregates, spheroids and tissue (Bayoussef, Dixon, Stolnik, & 
Shakesheff, 2012; Rampersad, 2012). Another consideration about the enhanced maintenance 
of cells when embedded in matrix is that the ECM might allow for some regeneration when 
cells are lost, which does not normally happen when cells are stored in suspension, as 
opposed to complete maintenance of the starting cell population. This could explain why in 
the storage experiments described in this chapter, viability indicator (%) was on average no 
lower than 75.5 % after 7 day storage at 37 ̊C and 20 % oxygen (the worst condition in terms 
of viability). The use of chondrogenic medium, as opposed to commercially available storage 
medium, might also play a role in preserving good cell viability even after 7 days. The 
presence of waste products such as lactate and NH3 have a toxic effect on cell growth and can 
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even inhibit proliferation (Hassell, Gleave, & Butler, 1991; Schop et al., 2009). Inhibiting 
values vary depending on the cell type and span from 10 mM to 40 mM for lactate and from 
0.5 mM to 40 mM for ammonia.  
 
Therefore the importance of finding a storage condition that would minimize their 
concentration in the spent medium after 7 day storage. Results described in this chapter 
showed that storage of scaffold free bone marrow derived cartilage discs for 7 days at 26 ̊C 
and 3 % oxygen led to lower NH3 release. This informative finding suggests that temperature 
is not the only parameter that should be controlled to enable successful storage of cell based 
medicinal products.  
A number of studies investigating factors influencing chondogenic differentiation of hMSCs 
have also considered oxygen (Boregowda et al., 2012; dos Santos et al., 2009; Panchalingam 
et al., 2015) and temperature (Mahmood S Choudhery et al., 2015; Schnitzler et al., 2015) 
separately but little to no evidence is available regarding the stability of these products once 
the differentiation process has taken place and without medium replenishment. Results 
described in this chapter show that COL2A1 and ACAN expression was not statistically 
different after 5 and 7 day storage in all storage conditions investigated. Inter-donor 
variability was observed and this might be linked to incorrect criteria to select healthy donors 
to extract bone marrow and isolate hMSCs from. While the use of cells or starting material 
from “healthy” donors as opposed to patients is common practice in research, it is important 
to add further selection criteria in order to limit biological variability. This will impact on the 
properties of the cell therapy product by affecting proliferation and, therefore, chondrogenic 
differentiation. This has been also shown in this study as the expression of COL1A1 was 
statistically different between the three donors and this might be also due to the differences in 
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proliferation of the cells. It has been demonstrated that chondrogenic differentiation of 
hMSCs is enhanced by high cell density (Murdoch et al., 2007). It is possible to use the data 
shown in this chapter to build models that will predict how viability, metabolites and gene 
expression will change in response to variations in temperature, oxygen and storage duration. 
This is the focus of chapter 3. 
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Chapter 3  
 
 
Factorial experimental design as an 
investigational and decision support tool for 
cell therapy product development  
 
 
 
 
 
Introduction  
 
 
In the previous chapter, the results of storage experiments for scaffold free bone marrow 
derived cartilage discs were presented. Eight different storage conditions were created by 
combining two levels of each factor under investigation: temperature (26,37 ̊C), oxygen (3,20 
%) and storage duration (5-7 days). These combinations correspond to the runs of a 2k full 
factorial design, where k is the number of factors under investigation (Montgomery, 2012). 
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The storage experiments were repeated for three healthy donors. While in chapter 2 each 
combination was considered as a separate treatment, here a system approach is used to 
investigate the effect of the input parameters (temperature, oxygen tension and storage 
duration) and system responses (viability, glucose, lactate, glutamine, ammonia). Eight 
response models were built by using data from three healthy donors presented in chapter 2 
(Fig.3.1). As raw data showed inter donor variability, donor number (donor #) was introduced 
in the model as an additional variable to mitigate the effect of biological variability. This 
technique is known as blocking (Montgomery, 2012) and increases the precision by which 
main effects and statistical significant interactions between factors are identified.  
 
 
Fig. 3.1 Statistical design of experiment schematic showing input and output factors selected. 
This system represents the storage of a cartilage disc, used as cell therapy model. For each input 
factor, two levels (high and low) have been selected creating eight combinations. Output values 
were measured for each sample as described in chapter 3. The experiment was performed for 
three healthy donors. As output data showed inter donor variability, one additional nominal 
variable, donor, has been introduced in the design to account for known variability introduced 
by noise (donor number) on the output factors. 
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Multifactorial design of experiment (DoE) is an important tool to identify main factors and 
interactions that would not be otherwise detectable using one-factor-at-a-time (OFAT) 
approach. It is widely used in the process industry, including the pharmaceutical industry 
(Rathore & Winkle, 2009). 
Applications of such a tool for investigation purposes, as in this study, have been rather 
limited ( Chen et al., 2011; Lim, Shunjie, Panoskaltsis, & Mantalaris, 2012). As adequate cell 
product characterization is a requirement in order to deliver market authorization (EMA 
website, http://www.ema.europa.eu/ema/), DoE could be introduced to gather more data 
about the product which will facilitate, in turn, the path towards market authorization.  
The response models generated can also be used to predict the value of system response 
parameters within the multidimensional space (Montgomery, 2012). While this cannot 
replace necessary data, it could be used to significantly reduce the number of experiments 
when limited resources are available, such as limited cell biopsy from the patient (Hourd et 
al., 2014). Two case studies are described in this chapter.   
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3.1 Material and methods  
3.1.1 Factorial Design of Experiment 
 
A full factorial three factor with two level design (23) has been implemented to study the 
effect of temperature, oxygen tension and storage duration on the preservation of cartilage 
discs used as cell therapy product model.  For each factor, two levels (high and low) have 
been selected, namely 26 °C and 37 °C for temperature, 3% and 20% for oxygen and 5 and 7 
days for storage duration. The experiments were repeated for three healthy donors as 
described in chapter 2. Data showed donor to donor variability. In order to improve the 
precision with which comparisons among factors of interest are made, one additional variable 
(donor number) was added to the design. This technique, referred to as blocking 
(Montgomery, 2012), reduces the variability introduced by known sources that are not of 
interest to the particular study. This study focused on the effect of temperature, oxygen level 
and storage duration rather than the difference between donors. Donor number becomes a 
nuisance factor and each level becomes a block: block 1 (donor #1), block 2 (donor #2) and 
block 3 (donor #3). All storage conditions created by combining different levels of the three 
factors under investigation, as described in table 3.2, are divided into these three blocks.  
Response variables have been selected on the basis of their biological properties, which are 
representative for this cell therapy model. Each response was an average value of triplicate 
measurements on the cartilage discs. JMP SAS software 
(http://www.jmp.com/en_gb/home.html) was used for all statistical analysis and data 
transformation. The software used multiple regression to fit a linear model for each response 
variable and parameter estimation was performed by least squares estimation. ANOVA was 
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used to identify main effects (factors which have a statistical significant effect on the 
response) and interactions between factors. Main effects on every response variable and 
interactions were evaluated by establishing statistical significance at p<0.05. 
 
3.1.2 Model adequacy checking  
 
The validity of the response models to identify the main effect and interactions was tested by 
the examination of residuals. A residual is defined as the difference between the 
experimentally observed value and the value predicted by the model (Montgomery, 2012).  
For a model to be valid, residuals need to have constant variance across the experimental 
range and not be systematically affected by the experimental order (Montgomery, 2012). This 
requirement can be tested by plotting the residuals versus the experimental run order and the 
residuals versus predicted values for that response variable. For the condition of constant 
variance, the former has to show no positive correlation, while the latter has to show no 
obvious pattern. If the variance of the observations increases as the magnitude of the 
observation increases, residuals in the plot would appear like an outward-opening funnel. 
Non constant variance would also indicate data are not normally distributed (Montgomery, 
2012). In case the variance is not constant across the experimental range, response can be 
transformed and the newly obtained variable modelled. One of the most commonly used 
transformations is the logarithmic transformation, where each data point is replaced by its 
log10 (Montgomery, 2012). For each response model, r2, which is the proportion of the 
variability in the data explained by the models, was also calculated by the JMP SAS software.  
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Response models were used for prediction. Function Profiler on JMP SAS software enables 
one to predict the value of each response variable within the space defined by temperature, 
oxygen and storage duration. 
3.1.3 Centre points and linearity assumption  
 
Response models estimated as described in 3.1.1 assume a linear relationship between input 
(temperature, oxygen tension, storage duration) and output factors (viability, glucose, lactate, 
glutamine, ammonia, COL2A1, ACAN, COL1A1). In order to confirm the linear relationship, 
three cartilage discs were prepared as described in 2.3. One disc was used as control (day 0, 
storage start) and the other two were stored at 31.5 °C, 11.5 % O2 for 6 days. This storage 
condition is in the middle of the investigational space defined by temperature range (26- 37 
°C), oxygen (3-20 % O2), storage duration (5-7 days). These data points are referred to as 
centre points and can be added to the 23 full factorial design described in 4.1.1 (Montgomery, 
2012). Viability, glucose, lactate, glutamine, ammonia, COL2A1, ACAN, COL1A1 were 
measured relative to the control disc not exposed to storage as described in chapter 3. These 
values were included in the response models and linearity assumption was tested by 
analysing goodness of fit and residuals plots.  
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3.1.4 Case study 1  
 
This case study describes how the eight response models presented in this chapter can be 
combined together and used to support the assessment of a storage container for cartilage 
discs. In this hypothetical scenario, two storage containers are available and two storage 
conditions (A and B) are simulated, as shown in Table 3.4. These sets of input parameters are 
within the investigated space which is described by the response models and, therefore, the 
values of viability, glucose, lactate, glutamine and ammonia in the spent medium and gene 
expression changes (COL2A1, ACAN and COL1A1) can be predicted selecting donor 1 as 
representative donor in the profiler function on JMP SAS software. 
 
Table 3.4 Simulated storage conditions (A and B) for cartilage discs (Case study 1). 
Storage 
Conditions 
Temperature 
(°C) 
Oxygen (%) Storage 
duration (days) 
A 32 20 6 
B 28 5 7 
 
Predicted values can be compared to acceptance thresholds which have been established for 
the cell therapy product based on clinical data.   
 
3.1.5 Case study 2 
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This case study describes another hypothetical scenario where the response models are used 
to inform the design of a customized storage container. The aim is to define a range for the 
three input parameters considered (temperature, oxygen and storage duration), which will 
lead to a cell therapy product that will meet set specifications of the output variables 
following storage. These specifications are linked to the quality attributes of the cell therapy 
product that can be defined during clinical development and are listed in Table 3.2. 
 
Table 3.2: Hypothetical list of quality attributes and specifications which need to be satisfied by 
the cartilage disc following storage.  
Quality attribute Specifications  
Viability ≥ 80 % 
Lactate  0-1.5 g/l 
NH3 0-0.5 mM 
Log10 COL2A1 0.4-0.55 
Log10 ACAN 0.40-0.60 
Log10 COL1A1 0.25-0.35 
 
 
By selecting donor 1 as representative donor and storage duration of 7 days, contour plots 
were created using JMP SAS software. These are a graphical representation of predicted 
output values versus two inputs modelled by the DoE (Tye, 2004). By overlaying the contour 
plots for viability, lactate, ammonia, log10COL2A1, log10ACAN, log10COL1A1, an area is 
defined which includes all combinations of temperature and oxygen that ensure specifications 
are satisfied.  
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3.2 Results 
 
3.2.1 Analysis of post-storage viability response model  
 
Cartilage discs were stored as described in Chapter 2. The eight storage conditions were 
created according to a 23 full factorial design and represent the combinations of two levels 
(high and low) of the three input parameters investigated: temperature, oxygen and storage 
duration. Response variables were viability, glucose, lactate, glutamine, ammonia, gene 
expression changes (Fig.3.1). The storage experiments were repeated for three healthy 
donors. As donor to donor variability was observed, one additional categorical variable 
“donor” was introduced to account for the effect introduced by the donor number on the 
response variables. Each response variable was analysed separately to identify factors (and 
interactions) which have a statistically significant effect. In order to identify statistically 
significant factors and interactions for the viability, the validity of the response model was 
tested by analysis of residuals (Fig. 3.2). Residuals show no outliers and no pattern, hence the 
validity of the viability response model was confirmed.  
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Fig. 3.2 Analysis of residuals for viability model. Residuals are plotted versus viability predicted 
values (A) and versus experimental run number (B) to confirm the hypothesis of constant 
variance. As no trend nor pattern is shown in (A) and (B) the model is valid. (C) shows goodnees 
of fit by plotting viability actual values versus viability predicted values. RSq= r2, RMSE=root 
mean square error.  
 
 
Fig. 3.3 shows how viability is predicted to vary when temperature, oxygen and storage 
duration vary within the investigated ranges for each donor. For all three donors, viability 
decreases as storage temperature or storage duration increases.  
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Fig. 3.3 Post-storage viability models for the process space under investigation. Models’ 
parameters estimation performed via least square estimation. Variability values are predicted 
for temperature range (26-37 °C), oxygen range (3-20%), storage duration 5-7 days and for 
donor 1 (A), 2 (B) and 3 (C) respectively. In red, viability predicted values for T= 31.5 °C, 
oxygen= 11.5 % and 6 day storage. Blue dashed lines and blue error bars represent 95 % 
confidence intervals. Temperature and storage duration have a statistical significant effect on 
viability, although the former is greater than the latter. Viability decreases as temperature and 
storage duration increase, while oxygen tension show no significant effect. Samples from the 
three donors studied showed consistent trends and inter-donor variability was not significant.  
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Consistenly for all three donors, temperature and storage duration have a statistically 
significant effect on viability (p=0.0003 and p=0.0243 respectively). Temperature has a 
greater effect on viability; lowering the temperature will improve the viability of the 
construct following storage. This is consistent with findings reported by Robinson, Picken & 
Coopman(2014). Lower temperature reduces cell metabolism as well as nutrient and oxygen 
demand and the tissue can be preserved ‘healthy’ for longer. Oxygen does not have a 
statistically significant effect on viability. It can be hypothesed that, as lowering the 
temperature reduces cellular metabolism, oxygen demand will also diminish and therefore its 
value does not impact cell viability after 5 or 7 days storage. The storage length (time) also 
has an effect on viability but not as strong as temperature (Fig. 3.3a). Viability of cell therapy 
products tend to diminish with shelf life (Reissis, García-Gareta, Korda, Blunn, & Hua, 
2013). As no interactions were statistically significant, temperature effect is independent of 
time. This translate in two important findings: temperature affects viability over storage 
period and, regardless of the temperature, viability will diminish with the shelf life of the 
product. As donor number has no significant effect on the response, it is possible to confirm 
that all three donors behaved in a consistent manner (Fig.3.3a,3.3b,3.3c). 
 
3.2.2 Analysis of post-storage glucose and lactate response models  
 
Glucose and lactate response models were created using data described in chapter 2. The 
validity of the glucose response model was checked by analysis of residuals (Fig 3.4). 
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Fig.3.4 Analysis of residuals for glucose model. Residuals are plotted vs glucose predicted values 
(A) and versus experimental run number (B) to confirm the hypothesis of constant variance. As 
no trend nor pattern is shown in (A) and (B) the model is valid. (C) shows goodnees of fit by 
plotting glucose actual values versus glucose predicted values. RSq= r2, RMSE=root mean 
square error. 
 
Once the validity of the model has been confirmed, glucose concentration in spent medium 
when temperature, oxygen tension and storage duration vary within the investigated ranges 
can be predicted (Fig. 3.5). Final glucose concentration in spent medium decreases as 
temperature increases.  
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Fig. 3.5 Post-storage glucose concentration models for the process space under 
investigation. Models’ parameters estimation performed via least square estimation. 
Glucose values are predicted for temperature range (26-37 °C), oxygen range (3-20%), 
storage duration 5-7 days and for donor 1 (A), 2 (B) and 3 (C) respectively. In red, 
glucose predicted values for T= 31.5 °C, oxygen= 11.5 % and 6 day storage. Blue dashed 
lines and blue error bars represent confidence intervals. Temperature and storage 
duration have a statistical significant effect on glucose consumption, although the former 
is greater than the latter. Final glucose concentration decreases as temperature and 
storage duration increase, while oxygen tension did not show significant effect. Samples 
from the three donors studied showed consistent trends but donor 2 was statistically 
different.  
 
 
 
Consistently for all three donors, temperature and storage duration have a statistically 
significant effect on glucose metabolism (p<0.0001 and p=0.0013 respectively). Temperature 
has a greater effect than time. Although glucose concentration will diminish over the storage 
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duration, temperature at which the cell product is stored is much more important in lowering 
its consumption. Oxygen has not a strong effect on glucose concentration at the end of the 5 
and 7 day storage. This is consistent with the fact that at lower temperature, oxygen demand 
will also decrease (Corwin et al., 2014). As the difference between donor numbers is 
statistically significant, it is possible to conclude that all three donors have not consistently 
metabolized glucose present in the culture medium during storage. No interactions had a 
statistically significant effect on glucose and, therefore, temperature and storage duration will 
independently affect glucose concentration in the spent medium.  
Similarly to glucose, lactate concentration variation can also be predicted. The validity of the 
model was checked by residuals analysis (Fig. 3.6).  
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Fig.3.6 Analysis of residuals for lactate model. Residuals are plotted versus lactate predicted 
values (a) and versus experimental run number (b) to confirm the hypothesis of constant 
variance. As no trend nor pattern is shown in (a) and (b) the model is valid. (c) shows goodnees 
of fit by plotting lactate actual values versus lactate predicted values. RSq= r2, RMSE=root 
mean square error.  
 
 
Once the validity of the model has been confirmed, lactate concentration in spent medium 
within the investigated range was predicted (Fig. 3.7). Consistently with glucose variation, 
lactate concentration increased with temperature and storage length.  
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Fig.3.7 Post-storage lactate concentration models for the process space under investigation. 
Models’ parameters estimation performed via least square estimation. Lactate values are 
predicted for temperature range (26-37 °C), oxygen range (3-20%), storage duration 5-7 days 
and for donor 1 (A), 2 (B) and 3 (C) respectively. In red, lactate predicted values for T= 31.5 °C, 
oxygen= 3-20 % and 6 day storage. Blue dashed lines and blue error bars represent confidence 
intervals.Temperature and storage duration have a statistical significant effect on lactate 
release, although the former is greater than the latter. Post storage concentration increases as 
temperature and storage duration increase, while oxygen tension did not show significant effect. 
Samples from the three donors studied showed consistent trends but donor 2 was statistically 
different.  
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Consistently for all three donors, temperature (p<0.0001) and storage duration (p<0.0001) 
had a statistically significant effect on lactate production (Fig. 3.7). This is consistent with the 
observed glucose metabolism. Temperature has a much greater effect than time. While 
oxygen does not have a significant effect on lactate production, its interaction with 
temperature is statistically significant (p=0.03) (Fig.3.8). This translates in the fact that 
oxygen will have an impact on lactate production which is dependent on the temperature; 
decreasing the oxygen tension from 20 % to 3 % during storage leads to an increased lactate 
production both at 5 and at 7 day storage. 
 
 
Fig. 3.8 Interaction plots for post storage lactate concentration model. All possible combinations 
of input variables (temperature, oxygen and storage duration) are shown. For each variable, red 
line represents low levels while blue line represents high levels. Statistically significant 
interactions towards post storage lactate concentration are represented by crossing lines. 
Oxygen and temperature interaction was statistically significant.  
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3.2.3 Analysis of post-storage glutamine and ammonia response models 
 
Glutamine is a non essential amino acid which is hydrolysed by glutaminase yielding 
glutamate and ammonia as waste products (Schop et al., 2009). In addition to glucose, 
glutamine can also be used to generate cellular energy. Glutamine concentration (mM) in 
spent medium was modelled using data described in chapter 2. 
 
 
Fig 3.9 Analysis of residuals for glutamine model. Residuals are plotted vs glutamine predicted 
values (a) and versus experimental run number (b) to confirm the hypothesis of constant 
variance. As no trend nor pattern is shown in (a) and (b) the model is valid. (c) shows goodnees 
of fit by plotting glutamine actual values versus glutamine predicted values. RSq= r2, 
RMSE=root mean square error.  
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Once the validity of the model has been confirmed, it was possible to evaluate main effect 
and potential interactions which have a statistically significant effect on glutamine (Fig. 
3.10). 
 
 
 
Fig. 3.10 Post-storage glutamine concentration models for the process space under investigation. 
Models’ parameters estimation performed via least square estimation. Glutamine values are 
predicted for temperature range (26-37 °C), oxygen range (3-20%), storage duration 5-7 days 
and for donor 1 (A), 2 (B) and 3 (C) respectively. In red, glutamine predicted values for T= 31.5 
°C, oxygen= 3-20 % and 6 day storage. Blue dashed lines and blue error bars represent 
confidence intervals. Temperature, oxygen and storage duration have a statistical significant 
effect on glutamine consumption, although the former is much greater. Post storage glutamine 
concentration decreases as temperature, oxygen and storage duration increase. Samples from 
the three donors studied showed consistent trends but donor 2 was statistically different.  
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Consistently for all three donors, temperature (p<0.0001), oxygen (p<0.0127) and storage 
length (p=0.0082) have significant effect on glutamine metabolism (Fig 3.10). As 
temperature and time interaction was also significant (p=0.0213), the effect of temperature on 
glutamine metabolism will depend on the storage length and in particular it will be greater for 
longer storage period. As shown in Fig. 3.10, temperature has a much greater impact than 
time and oxygen decreasing glutamine. As it can be also noticed in Fig 3.10, donor #2 shows 
a statistically significant difference compared to donor #1 and donor #3 which is probably 
due to the difference in terms of number of cells per disc.  Closely linked to glutamine 
metabolism, post-storage ammonia concentration in spent medium was also analysed.   
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Fig. 3.11 Analysis of residuals for NH3 model. Residuals are plotted vs ammonia predicted 
values (a) and versus experimental run number (b) to confirm the hypothesis of constant 
variance. As no trend nor pattern is shown in (a) and (b) the model is valid. (c) shows goodnees 
of fit by plotting ammonia actual values versus ammonia predicted values. RSq= r2, 
RMSE=root mean square error.  
 
 
Once the validity of the model has been checked, the concentration of ammonia in the spent 
medium was predicted (Fig. 3.12). 
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Fig.3.12 Post-storage NH3 concentration models for the process space under investigation. 
Models’ parameters estimation performed via least square estimation. NH4+ values are 
predicted for temperature range (26-37 °C), oxygen range (3-20%), storage duration 5-7 
days and for donor 1 (A), 2 (B) and 3 (C) respectively. In red, NH4+ predicted values for 
T= 31.5 °C, oxygen= 3-20 % and 6 day storage. Blue dashed lines and blue error bars 
represent confidence intervals. Temperature, oxygen and storage duration have a 
statistical significant effect on ammonia release, although the former is greater. Post 
storage ammonia concentration increases as temperature, oxygen and storage duration 
increase, while oxygen tension did not show significant effect. Samples from the three 
donors studied showed consistent trends but donor 2 was statistically different.  
 
 
 
Consistently for all three donors, temperature (p<0.0001), oxygen (p<0.0001) and storage 
length (p= 0.0051) significantly affected ammonia production. The interaction temperature-
time was also statistically significant, consistently with glutamine (Fig. 3.13).  
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Fig. 3.13 Interaction plots for post storage NH3 concentration model. All possible combinations 
of input variables (temperature, oxygen and storage duration) are shown. For each variable, red 
line represents low levels while blue line represents high levels. Statistically significant 
interactions towards post storage lactate concentration are represented by crossing lines. 
Oxygen and temperature interaction was statistically significant.  
 
 
Interestingly, Fig. 3.12 shows that the effect of temperature and oxygen on ammonia 
production is greater than the storage duration, unlike for glutamine. For both glutamine and 
NH3, all three input variables (temperature, oxygen tension and storage length) are 
statistically significant as well as temperature and time interaction. This suggests that storage 
parameters can be engineered in order to guide cells towards a specific metabolic pathway 
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(glucose or glutamine metabolism), minimize waste product release and improve cell product 
preservation during storage.  
 
 
3.2.4 Analysis of post-storage gene expressions response models 
 
Other than viability, preservation of biological function of cell therapy product is important to 
prove safety and efficacy of the medicinal product. In this study, it has been assumed that the 
mechanism of action for this product would be to engraft and stimulate regeneration of 
cartilage. Gene expression was therefore considered a potential potency assay, linked to the 
biological property of the tissue. For cartilage tissue, it is important to retain COL2A1 and 
ACAN expression, while the expression of fibroblast genes like COL1A1 should be minimal. 
Initially, the validity of the COL2A1 response model was checked by residual analysis 
(Fig.3.14).  
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Fig. 3.14 Analysis of residuals for COL2A1 model. Residuals are plotted vs COL2A1 predicted 
values (a). Residuals showed uneven spreading (fanning effect) which violets the assumption of 
constant variance. COL2A1 values were transformed by log10. Residuals for the transformed 
COL2A1 values (LOG10COL2A1) are plotted versus predicted LOG10COL2A1 (b). No fanning 
is shown in (b) and the model can therefore be considered valid. (c) shows goodnees of fit by 
plotting LOG10COL2A1 actual values versus predicted values. RSq= r2, RMSE=root mean 
square error. 
 
 
At first, residuals showed a pattern, known as “fanning” where the variance increases with 
the predicted values (Fig 3.14a). This effect highlights that the variance is not constant within 
residuals (Montgomery, 2012). COL2A1 values were then transformed by log10. The fanning 
effect was removed and residuals showed no trends (Fig.3.14b). 
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Fig. 3.15 shows the variation of Log10COL2A1 within the range of temperature, oxygen and 
storage duration considered. Temperature, oxygen and storage duration did not have a 
statistically significant effect on the expression of COL2A1. Furthermore, COL2A1 variation 
was characterized by very high donor to donor variability. 
 
 
Fig. 3.15 Post storage COL2A1 expression fold change relative to non-stored samples 
models for the process space under investigation. Fold change values were transformed 
by log10. Models’ parameters estimation performed via least square estimation. Log10 
of COL2A1 fold change values are predicted for temperature range (26-37 °C), oxygen 
range (3-20%), storage duration 5-7 days and for donor 1 (A), 2 (B) and 3 (C) 
respectively. In red, log10 fold changes COL2A1 predicted values for T= 31.5 °C, 
oxygen= 3-20 % and 6 day storage. Blue dashed lines and blue error bars represent 
confidence intervals. Temperature, oxygen tension and storage duration did not have a 
statistical significant effect on COL2A1 expression. Samples from the three donors 
studied showed consistent trends but donor 1 expressed higher COL2A1 values 
compared to donor 2 and 3.  
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Similarly to COL2A1, ACAN variation was also modelled. To test the validity of the model, 
residuals have been plotted and analysed (Fig 3.16a). Fanning was also present here as in 
COL2A1 and data were then transformed by log10. Fanning effect was removed and residuals 
were randomly distributed (Fig. 3.16b).  
 
Fig. 3.16 Analysis of residuals for ACAN model. Residuals are plotted vs ACAN predicted values 
(a). Residuals showed uneven spreading (fanning effect) which violets the assumption of 
constant variance. ACAN values were transformed by log10. Residuals for the transformed 
ACAN values (LOG10ACAN) are plotted versus predicted LOG10ACAN (b). No fanning is 
shown in (b) and the model can therefore be considered valid. (c) shows goodnees of fit by 
plotting LOG10ACAN actual values versus predicted values. RSq= r2, RMSE=root mean 
square error. 
 
 
 
The expression of ACAN increased with temperature and oxygen while it decreases with 
storage duration but none of these factors were statistically significant (Fig. 3.18).  
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Fig. 3.17 Post storage ACAN expression fold change relative to non-stored samples models for 
the process space under investigation. Fold change values were transformed by log10. Models’ 
parameters estimation performed via least square estimation. Log10 of ACAN fold change 
values are predicted for temperature range (26-37 °C), oxygen range (3-20%), storage duration 
5-7 days and for donor 1 (A), 2 (B) and 3 (C) respectively. In red, log10 fold changes ACAN 
predicted values for T= 31.5 °C, oxygen= 3-20 % and 6 day storage. Blue dashed lines and blue 
error bars represent confidence intervals. Temperature, oxygen tension and storage duration 
did not have a statistical significant effect on ACAN expression. Samples from the three donors 
studied showed consistent trends but donor 1 was statistically different. 
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COL1A1 model was also analysed (Fig. 3.18a). Due to the presence of fanning in the 
residuals, COL1A1 data points were transformed by log10 (LOG10COL1A1) (Fig.3.18b). 
  
 
Fig. 3.18 Analysis of residuals for COL1A1 model. Residuals are plotted vs COL1A1 predicted 
values (a). Residuals showed uneven spreading (fanning effect) which violets the assumption of 
constant variance. COL1A1 values were transformed by log10. Residuals for the transformed 
COL1A1 values (LOG10COL1A1) are plotted versus predicted LOG10COL1A1 (b). No fanning 
is shown in (b) and the model can therefore be considered valid. (c) shows goodnees of fit by 
plotting LOG10COL1A1 actual values versus predicted values. RSq= r2, RMSE=root mean 
square error. 
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Fig. 3.19 Post storage COL1A1 expression fold change relative to non-stored samples 
models for the process space under investigation. Fold change values were transformed 
by log10. Models’ parameters estimation performed via least square estimation. Log10 of 
COL1A1 fold change values are predicted for temperature range (26-37 °C), oxygen 
range (3-20%), storage duration 5-7 days and for donor 1 (A), 2 (B) and 3 (C) 
respectively. In red, log10 fold changes COL1A1 predicted values for T= 31.5 °C, oxygen= 
3-20 % and 6 day storage. Blue dashed lines and blue error bars represent confidence 
intervals. Temperature, oxygen tension and storage duration did not have a statistical 
significant effect on COL2A1 expression. Samples from the three donors studied showed 
consistent trends but were statistically different.  
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Temperature (p<0.0007), storage duration (p=0.0086) and oxygen (0.0114) were all 
statistically significant. Unlike COL2A1 and ACAN which were upregulated, COL1A1 was 
also down regulated for donor #1 compared to the other donors. This can be explained by the 
highest proliferation of the cells in the transwell which correlates to better chondrogenesis 
and, therefore, reduced expression of COL1A1. Storage conditions can therefore be 
engineered to preserve a chondrogenic-like phenotype and minimize the expression of 
fibroblastic genes like COL1A1.  
It was interesting to notice that preferential storage conditions in terms of viability, lactate 
and ammonia production, COL2A1 and ACAN production are the ones that lead to 
upregulation of COL1A1, which should be minimal for cartilage-like tissue. This suggests 
that multiple factors should not be analysed nor controlled independently as the preferred 
outcome might only be achieved by adequately combining input factors.  This concept is the 
basis for the following case studies.  
 
3.3 Linearity testing and centre points  
 
Response models described in this chapter assume the presence of a linear relationship 
between input and output factors. In order to further investigate this linearity, two additional 
cartilage discs, cultured as described in 3.1.3, were stored at 31.5 °C, 11.5 % oxygen for 6 
days (centre points storage conditions). Viability, glucose, lactate, glutamine, ammonia and 
gene expression changes were measured following storage under these centre point 
conditions. Results are shown in table 3.3. 
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Table 3.3 Centre points response values. CP1 (centre point 1), CP2 (centre point 2). Values are 
expressed as mean ±SEM for three technical replicates from one healthy donor 
 Viability Glucose  Lactate Glutamine Ammonia COL2A1 ACAN COL1A1 
CP1 0.05±0.006 3.36±0.075 1.11±0.035 0.445±0.045 0.73±0.41 8.10±0.44 0.41±0.29 1.69±0.33 
CP2 0.04±0.002 3.34±0.053 1.18±0.045 0.34±0.061 0.75±0.032 7.15±0.33 0.47±0.43 1.72±0.41 
 
 
These center points were added to the 23 full factorial design. Response models were checked 
again to identify potential lack of fit due to the centre points. Fig. 3.20 compares viability 
response models with and without centre points.   
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Fig. 3.20 Center points analysis on viability model. (Top) Viability model with center points. 
Viability values measured plotted versus predicted values showing the presence of two outliers 
which correspond to center points (blue circle) (a) Lack of fit due to center points was observed. 
Residuals are plotted versus predicted values (b) and versus experimental run (c), confirming the 
presence of outliers (centre points). (Bottom)Viability model after center points removal (d). No 
lack of fit was observed. Residuals plotted versus predicted values (e) and experimental run (f) 
showed no correlations and no trends confirming the hypothesis of constant variance.  
 
Lack of fit due to centre points was observed. The presence of lack of fit due to center points 
leads to hypothesis of curvature in the system (i.e. non linear relationship between input and 
output parameters). However, this would require additional data points. As this was not 
possible in this study, linearity was assumed correct and lack of fit introduced by centre 
points due to time-dependent variation not captured by the model. This could be explained by 
the fact that these centre points were performed at a later time.  
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3.4 Case study 1  
 
The eight response models described in this chapter highlight that parameters have a 
contrasting effect on the biological properties of the cell product following storage. When 
used in combinations, these models can provide useful information about the biological 
properties of the product while reducing the number of experiments. Assuming the storage of 
the cell therapy product under investigation in two simulated storage conditions (A and B), 
the response models were used to predict the output values given these combinations of input 
factors. Results are shown in Fig. 3.21 for storage condition A and Fig.3.22 for storage 
condition B.  
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Fig. 3.21 Output values prediction for simulated storage condition A (T = 32 °C, oxygen = 20 %, 
storage duration= 6 days). Vertical red dashed lines indicate selected input values in the Profiler 
function in JMP SAS software. Horizontal red dashed lines represent output predicted values 
for each response variable. Predicted values are also indicated in red for each response variable 
with 95 % confidence intervals (CIs).  Blue dashed lines represent 95 % CIs for the predicted 
values within the investigated range of input factors. 
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Fig. 3.22 Output values prediction for simulated storage condition B (T=28 °C, oxygen = 5 %, 
storage duration= 7 days). Vertical red dashed lines indicate selected input values in the Profiler 
function in JMP SAS software. Horizontal red dashed lines represent output predicted values 
for each response variable. Predicted values are also indicated in red for each response variable 
with 95 % confidence intervals (CIs).  Blue dashed lines represent 95 % CIs for the predicted 
values within the investigated range of input factors.  
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These predicted values can then be compared to acceptance criteria established for that 
product during clinical development and support the establishment of a successful storage 
solution. Although confirmatory and validation experiments will be necessary, this will 
considerably reduce the number of experiments needed during the procurement phase of the 
container.  
 
 
 
3.5 Case study 2  
 
Similarly to what was described in 3.2.5, the response models can be used to identify the 
optimal input parameter settings that will lead to the desired outcome. This data can then 
inform the design of an ad hoc storage or transport container. As discussed in chapter 1, 
storage and transportation of a cell based medicinal product can be considered the last 
manufacturing step. Results described in this chapter showed that within the process space 
under investigation (temperature=26-37 °C, oxygen tension= 3-20% and storage duration=5-
7 days), process parameters affect response variables in contrasting ways. In order to define 
an optimal set of input parameters (process parameters) for a storage container within the 
defined process space, response models can be combined. Spefications can be selected for all 
the relevant quality attributes of the product: viability, lactate and NH3 maximum accaptable 
release and log10 of COL2A1, ACAN and COL1A1 fold changes relative to non-stored discs. 
Assuming a storage duration of 7 days, for each response variable all possible combinations 
of temperature and oxygen which meet the set specification have been defined. These are 
represented by contour plots (Fig.3.23). By overlaying contour plots for all response variables 
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considered, an optimal process space was identified. This is represented as a white area in a 
graph of temperature versus oxgen (Fig.3.23,H) .  
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Fig.3. 23 Contour plots 7 day storage of cartilage disc. The set specifications were (B) 
viability ≥ 80 %, (C) lactate concentration in spent medium after storage 0-1.5 g/l, (D) NH3 
concentration 0-0.5 mM, (E) log10 of COL2A1 fold change relative to non-stored discs 0.4-
0.55, (F) log10 of ACAN fold change relative to non-stored discs 0.40-0.6 (G) log10 of 
COL1A1 fold change relative to non-stored discs -0.35 to -0.25 (H) Design space for the 
process space under investigation. White areas represent combinations of temperature and 
oxygen which would meet the set specifications (B-G). Design space shown in H is given by 
overlapping colored areas B-G. Each point within the white area in H will meet all 
specifications. A point can be selected within the design space to test the robustness of the 
system (I).  
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3.6 Discussion 
 
 
Statistical design of experiment (DoE) has been successfully used in many industries, such as 
automotive (Valles & Sanchez, 2009), medical device (Eatock, Dixon, & Young, 2009), 
semiconductor (Joshi, 1991) and pharmaceutical (Rathore & Winkle, 2009). More recently, it 
has been applied as a tool to investigate the simultaneous involvement of factors and their 
interactions during in vitro differentiation of stem cells (Sotiropoulou, Perez, Salagianni, 
Baxevanis, & Papamichail, 2006), osteogenic differentiation (Decaris & Leach, 2011) and the 
culture of human embryonic stem cells in stirred tank bioreactors (M., MengGuoliang, E., D., 
& S., 2013).  
In this chapter, DoE has been applied to investigate the simultaneous effects of temperature, 
oxygen and storage duration on the biological properties of cartilage discs used as a cell 
therapy model. 
Temperature is the most commonly studied parameter modulating the biopreservation of cell 
therapy products (Garrity, Stoker, Sims, & Cook, 2012)(Stolzing & Scutt, 2006)(Stolzing, 
Sethe, & Scutt, 2006). For the cell therapy product described here, temperature had a 
statistically significant effect on viability, glucose, lactate, glutamine, ammonia and COL1A1 
expression. Oxygen had a statistically significant effect on glutamine and NH3 concentration 
and on COL1A1 expression. Oxygen and temperature interaction showed a statistically 
significant effect on lactate metabolism, which could not have been detected by a traditional 
one-factor-a time approach (Montgomery, 2012). This finding implies that the temperature 
mediated decrease in lactate released by the cell therapy product in the medium will be 
depended on the oxygen tension present in the medium.  
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Storage duration showed a statistically significant effect on viability, glucose, lactate, 
glutamine, ammonia and COL1A1. 
The analysis of these models showed the input factors investigated have a contrasting effect 
on some of the biological properties of the product following storage. In particular, 
preferential storage conditions in terms of viability, lactate and ammonia production, 
COL2A1 and ACAN production are the ones that lead to upregulation of COL1A1, which 
should be minimal for cartilage-like tissue. 
Other than investigational purposes, this system approach can be also used as a decision 
support tool for process development by combining the response models. As demonstrated in 
case study 1, response values for simulated storage conditions can be predicted. This can 
limit the number of experiments needed to evaluate a new container for storage of a cell 
therapy product, like the one described in this chapter. This application can be particularly 
useful for autologous product development, where the amount of biological material available 
is rather limited (I. Martin et al., 2014). 
An additional application is the use of these response models to identify optimal set of input 
parameters which will enable a product within specifications (case study 2). 
The response models described in this chapter suffer from one main limitation: assumption of 
linearity that could not be verified with the presence of centre points. This study could be 
further expanded with the addition of axial point, a method referred to as central composite 
design (Montgomery, 2012).  
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The addition of points to confirm the presence of curvature and other factors which might 
have an effect, can improve the accuracy of these models in predicting response values. This 
is out of the scope of this thesis, as described in chapter 5.  
Once optimal input values have been determined, Monte Carlo simulations can be performed 
to account for uncertainly in input values (W. Schneider, Bortfeld, & Schlegel, 2000). 
If these response models were to be used as decision support tools for designing a container 
for storage and transportation of the cell therapy product, it would be useful to determine the 
probability of the output parameters (quality attributes) to be off specifications.   
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Chapter 4 
  
 
 
Investigating storage properties of hMSCs 
prior to their differentiation  
 
 
 
 
 
 
Introduction  
 
 
As discussed in chapter 1, hMSCs have been advocated as a useful “living” active 
pharmaceutical ingredient for cell therapy applications with over 400 clinical trials currently 
ongoing (clinicaltrials.gov). These cells can be isolated from a number of tissues including 
bone marrow (Capelli et al., 2015), adipose tissue (Rasini et al., 2013), cord tissue (M S 
Choudhery, Badowski, Muise, & Harris, 2013).  
The effect of low oxygen tension (hypoxia) on hMSCs expansion has been investigated 
mainly in order to improve cell expansion yields (Dos Santos et al., 2010). However, little is 
known as to whether temperature and oxygen can orchestrate a stimulation pattern which 
enhances or inhibits the biological properties of hMSCs. A deeper understanding of 
temperature and oxygen effect on hMSCs could facilitate the design of innovative solutions 
for storage and transportation solutions for cell therapy medicinal products. Moreover, 
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hypoxic pre-conditioning have been shown to enhance the therapeutic potential for hMSCs 
(Chang et al., 2013). In this study, only the ability of hMSCs to differentiate into the three 
lineages (chondrogenic, osteogenic and adipogenic) has been investigated along with the 
metabolic activity over the 5 day storage period. 
 
Similarly to what was described in chapters 2 and 3, the combined effect of temperature and 
oxygen was studied for hMSCs when stored in the controlled environment provided by four 
tissue culture incubators. The same ranges were selected for temperature (26-37 °C) and 
oxygen (3-20 %).  Storage duration was limited to five days (Fig. 4.1). 
 
 
Fig. 4.1 Multifactorial space under investigation for hMSCs. Four storage conditions were 
defined by combining two levels (high and low) for the two factors: temperature and oxygen  
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4.1 Materials and methods 
 
 
4.1.1 Storage of hMSCs in tissue culture flasks and plates 
 
hMSCs from three healthy donors (Lonza Biosciences) were isolated from bone marrow as 
described in Chapter 2 paragraph 1.1. hMSCs were expanded in T-75 flasks with 
Mesenchymal Stem Cell Growth Medium (Lonza, cat. No. PT-3001) supplemented with 5 
ng/ml fibroblast growth factor-2 (FGF2, R&D Systems). Upon reaching passage 4 (P4), cells 
were seeded into T-25 flasks at a seeding density of 104 cells/cm2. Each flask corresponded to 
a different storage condition. The flasks were then placed in 4 incubators providing 4 
different storage conditions as shown in Table 4.1. After 5 day storage, cells were 
differentiated towards chondrogenic, osteogenic and adipogenic lineage and spent medium 
metabolites measured (Fig. 4.1). Three flasks which have not been exposed to any storage 
period were also differentiated towards the three lineages and used as controls (one for each 
donor). Additionally, hMSCs from one healthy donor were also seeded in 24-well plates at 
the same seeding density and stored under the same conditions as the flasks (Table 4.1) and 
after 5 days these cells were differentiated towards osteogenic and adipogenic lineages. Each 
plate corresponds to a different storage condition and lineage differentiation. For each plate, 3 
wells were seeded. Two plates were not exposed to any storage conditions and the hMSCs 
were differentiated towards osteogenic and adipogenic lineage on the same day the storage 
period started. These plates were used as control.  
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Table 4.1. Storage conditions for hMSCs seeded in T25 flasks and 24 well plates. Storage 
duration was 5 days. 
Run Temperature (°C) Oxygen (%) 
1 37 20 
2 37 3 
3 26 20 
4 26 3 
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Fig. 4.2 Storage experiments schematic. hMSCs from three healthy donors were seeded in T25 
flasks and exposed to different combinations of temperature and oxygen for 5 days (Table 4.1). 
Stored hMSCs were then differentiated towards chondrogenic (A), osteogenic (B) and 
adipogenic (C) lineages. Non stored hMSCs were also differentiated towards the three lineages 
on the day the storage period started (day 0) and used as control. Spent medium was also 
analysed for glucose, lactate, glutamine and NH3 concentrations. For osteogenic (B) and 
adipogenic (C) lineages  hMSCs were also seeded, stored and differentiated in 24 well plates. 
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4.1.2 Spent medium analysis 
 
To quantify the metabolite concentration of hMSCs after storage, spent medium was 
aseptically removed from the T-25 flasks after the storage period and stored at -80 °C in 
plastic tubes (Eppendorfs). Fresh Mesenchymal Stem Cell Growth Medium (Lonza, cat. No. 
PT-3001) samples were also included as control. Stored samples were then thawed and run 
on the Bioprofile FLEX bioanalyser (Nova Biomedical) for analysis of glucose [g/l], lactate 
[g/l], glutamine [mM] and ammonium [mM] concentrations. As 3 ml of spent medium were 
available for each storage condition and 1ml if required for each measurement, three 
technical repeats were performed.  
 
4.1.3 Post-storage chondrogenic differentiation in micropellets 
 
Following 5 day storage under the conditions shown in Table 4.1, hMSCs were washed with 
pre-warmed PBS (Sigma) before being detached from the T25 flasks via 1 ml trypsin 
digestion. For each storage condition, three flasks were studied corresponding to three 
healthy donors. hMSCs from each flask were centrifuged in 15 ml falcon tubes at 240 x g for 
5 minutes. Supernatant was discarded and 5 ml of pre-warmed PBS was added to each falcon 
tube. Cells were then centrifuged again at 240 x g for 5 minutes. Supernatant was discarded 
and the cells were re-suspended in 1 ml of chondrogenic medium (Table 2.1, chapter 2). 
Three micropellets were prepared for each storage condition and each donor by seeding 
150000 hMSCs per well in a non-treated V-bottom 96 well plate (Greiner) which had been 
previously UV-irradiated for 30 minutes. Following seeding, chondrogenic medium was 
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added to a final volume of 200 l per well. The plate was then centrifuged at 500 g for 5 
minutes. PBS was added to border wells to prevent evaporation loss. Chondrogenic medium 
was replenished every 3 days for 14 days. The same procedure was used to prepare 
micropellets from flasks not exposed to storage (one for each donor). Chondrogenic 
differentiation of micropellets was compared to micropellets not exposed to storage.  
 
4.1.4 Post-Storage osteogenic differentiation  
 
Following 5 day storage under the conditions shown in Table 4.1, hMSCs in flasks and plates 
were washed with pre-warmed PBS (Sigma) before adding 3 ml per flask and 500 l per well 
of osteogenic medium respectively (Table 4.2). Osteogenic medium was replenished every 3 
days for 14 days. Light microscopy images were also taken to confirm osteogenic 
differentiation.  
 
Table 4.2 Osteogenic medium 
Reagent Supplier Function 
Low glucose DMEM Gibco –Life 
technologies  
Enables cell growth and proliferation. (Z. 
Yang & Xiong, 2012) 
2 mM L-glutamine Sigma-Aldrich, 
Poole, UK 
Essential amino acid required for cell growth 
(Z. Yang & Xiong, 2012). 
10 % v/v foetal 
bovine serum 
Sigma-Aldrich, 
Poole, UK 
Enables cell attachment to surface and 
growth (Z. Yang & Xiong, 2012) 
0.1 M 
Dexamethasone 
 
Sigma-Aldrich, 
Poole, UK 
Enhances the osteoblastic differentiation of 
hMSCs(Sun, Wu, Dai, Chang, & Tang, 
2006) 
10 mM -
glycerophosphate 
Sigma-Aldrich, 
Poole, UK 
Promotes mineralization of hMSCs (Schäck 
et al., 2013) 
50 M ascorbic acid Sigma-Aldrich, 
Poole, UK 
Stimulates secretion of collagen and 
glycosaminoglycan (Eslaminejad et al., 
2013) 
100 U/ml penicillin, 
100 g/ml 
streptomycin 
Gibco –Life 
technologies 
Used in culture media to mitigate risk of 
bacterial and fungal infections. 
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4.1.5 Post storage adipogenic differentiation 
 
Following 5 day storage under the conditions shown in Table 1, hMSCs from flasks and 
plates were preliminary washed with pre-warmed PBS (Sigma) before adding 3 ml per flask 
and 500 l per well of adipogenic induction medium respectively (Table 4.3). Adipogenic 
induction medium was removed at day 3 and replaced with adipogenic manteinance medium 
(Table 4.4) which was replenished two days later. On day 7, this cycle was repeated for a 
total adipogenic differentiation period of 14 days. Light microscopy images were also taken 
to confirm adipogenic differentiation.  
 
Table 4.3 Adipogenic induction medium 
Reagent Supplier Function 
4g/L DMEM  Gibco –Life 
technologies 
Enables cell growth and proliferation. (Z. Yang 
& Xiong, 2012) 
10% (v/v) FBS  
 
Sigma-Aldrich, 
Poole, UK 
Enables cell attachment to surface and growth 
(Yang & Xiong, 2012) 
1µM 
dexamethasone 
Sigma-Aldrich, 
Poole, UK 
Contributes to hMSCs differentiation (Scott, 
Nguyen, Levi, & James, 2011) 
100U/ml 
penicillin  
100µg/ml 
streptomycin 
Gibco –Life 
technologies 
Used in culture media to mitigate risk of 
bacterial and fungal infections. 
0.65 mM 3-
isobutyl-1- 
methylxanthine 
(IBMX)  
Gibco –Life 
technologies 
Stimulates adipogenic differentiation in hMSCs 
(Scott et al., 2011) 
Insulin grow 
factor (IGF-1) 20 
nM  
Gibco –Life 
technologies 
Induces adipogenic differentiation (Scott et al., 
2011) 
Rosiglitazone 
20mM 
Gibco –Life 
technologies 
Stimulates adipogenesis in hMSCs (Rosen & 
MacDougald, 2006) 
10µg/ml insulin Gibco –Life 
technologies 
Stimulates glucose metabolism and lipid uptake 
(Rosen & MacDougald, 2006) 
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Table 4.4 Adipogenic mantainance medium 
Reagent Supplier Function 
4g/L DMEM  Gibco –Life 
technologies 
Enables cell growth and proliferation. (Yang & 
Xiong, 2012) 
10% (v/v) FBS  
 
Sigma-Aldrich, 
Poole, UK 
Enables cell attachment to surface and growth 
(Yang & Xiong, 2012) 
100U/ml 
penicillin 
100µg/ml 
streptomycin 
Gibco –Life 
technologies 
Used in culture media to mitigate risk of 
bacterial and fungal infections. 
 
10µg/ml insulin Gibco –Life 
technologies 
Stimulates glucose metabolism and lipid uptake 
(Rosen & MacDougald, 2006) 
 
 
4.1.6 Post storage GAGs assay  
 
Following storage, hMSCs were differentiated towards the chondrogenic lineage as described 
in 4.3. Sulfated glycosaminoglycan production was quantified via the dimethylmethylene 
blue (DMB) assay as described by Kafienah and Sims (Kafienah & Sims, 2004). Micropellets 
were collected and washed with PBS (Sigma) before being stored at -80 °C. On the day the 
assay was performed, samples were thawed and placed into 1.5 ml tubes (Sarstedt). 
Micropellets were then digested by adding 70 l of phosphate buffer (0.1 M pH 6.5, Sigma 
Aldrich), and 40 l of the digestion solution (Table 4.5).  
 
Table 4.5 Micropellet digestion solution 
Reagent Concentration Supplier 
Papain 20 l (0.25 g in 10 ml 0.1M 
phosphate buffer pH 6.5)  
Sigma-Aldrich, Poole, UK 
Cystein-HCl 10 l (0.078 g in 10 ml 0.1M 
phosphate buffer pH 6.5) 
Sigma-Aldrich, Poole, UK 
EDTA 10 l (0.19g in 10 ml 0.1 M 
phosphate buffer pH 6.5) 
Sigma-Aldrich, Poole, UK 
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Tubes were then incubated overnight at 65 °C. DMB stock solution was prepared by 
dissolving 16 mg DMB powder (Sigma-Aldrich, cat. No. 34088) in 900 ml double distilled 
water in a glass bottle covered with aluminium foil containing 3.04 g glycine (sigma-Aldrich) 
and 2.73 g of NaCl (Sigma-Aldrich). This was mixed for 2 hours and the pH adjusted to 3.0 
with HCl (Sigma) to a final volume of 1 L. The solution was stored at room temperature in 
the glass bottle covered with aluminium foil. In order to make a standard curve, chondroitin 
sulphate (Sigma-Aldrich) was prepared in water in a 1 mg/ml stock solution and kept 
refrigerated. Nine tubes were prepared with known concentration of chondroitin sulphate as 
described in Table 4.6.  
Table 4.6 Chondroitin sulphate calibration curve  
Standard (g/ml) Phosphate Buffer (l) Chondroitin sulphate (l) 
0 200 0 
5 199 1 
10 198 2 
15 197 3 
20 196 4 
25 195 5 
30 194 6 
35 193 7 
40 192 8 
 
Overnight digested samples were diluted (1:4) and for each sample 40 l were added to a 96 
well plate (Grainer) in triplicates. For each standard (Table 4.6), 40 l were also added to the 
plate in triplicates. Two hundred and fifty l of DMB stock solution were then added to each 
well and absorbance was read at 530 nm using a TECAN plate reader and Xflor 4 software. 
GAG values in g/ml were then normalized with the amount of DNA per micropellet 
measured via Picogreen assay as described in chapter 2 paragraph 1.4. From each digested 
sample, three technical repeats were performed by adding 25 l of DNA containing sample to 
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75 l of Tris-EDTA buffer. The amount of DNA per micropellet was calculated as the 
average of the three values. 
 
 
4.1.7 Post-storage alkaline phosphatase assay and osteogenic staining  
 
Following storage in 24 well culture plates (Table 4.1), hMSCs were induced to differentiate 
into the osteogenic lineage as described in 4.4. The osteogenic differentiation potential was 
tested by alkaline phosphatase (ALP) assay. ALP is a membrane bound enzyme that is used a  
as marker for osteogenic differentiation (Müller et al., 2007). This can be indirectly measured 
by the amount of para-nitrophenol, which is yellow when hydrolysed by alkaline 
phosphatase. P-nitrophenol (pNPP) is formed by its substrate (p-nitrophenyl phosphate) in 
presence of ALP. Absorbance can be measured at 405 nm and the amount of p-nitrophenol 
can be correlated to the amount of ALP (Matsubara et al., 2004). After 14 days osteogenic 
differentiation, hMSCs were washed with warm PBS and fixed with 4% (w/v) 
paraformaldehyde for 5-10 min. This was removed and fixed cells were washed in PBS Tris 
buffer pH 8.3 for 5 minutes. Three hundred l of alkaline phosphate yellow liquid substrate 
for ELISA (Sigma Aldrich) was added to each well. Plates were covered with aluminium foil 
and incubated at room temperature for 30 minutes. After incubation, yellow substrates from 
each well were transferred to a 96 well plate in triplicates and absorbance measured at 
405nm, using a TECAN plate reader and Xflor 4 software. A standard curve was prepared by 
adding 20 l of 10 mM p-nitrophenol standard (Sigma) in 1 ml of PBS Tris buffer pH 8.3 and 
creating serial dilutions to give a concentration range of 200, 100, 50, 25, 12.5 and 6.25 M. 
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Following enzymatic reaction, cells were washed with PBS Tris buffer pH 8.3 for 5 minutes 
before being incubated with the osteogenic staining solution (Table 4.7) for 20 minutes.  
Table 4.7 Osteogenic staining solution  
Reagent Quantity Supplier 
Napthol AS phosphate  0.005 g in 200 l of NN- 
Dimethylformaldeide 
(DMF) 
Sigma Aldrich  
Fast Blue Salt 0.03 g in 50 ml PBS Tris 
Buffer pH 8.3 
Sigma Aldrich 
 
 
Stained cells were washed with PBS and then visualized by brightfield microscopy (Zeiss 
Axio Imager 2 microscope). 
 
 
 
 
4.1.8 Post storage adipogenic staining of hMSCs 
 
The adipogenic differentiation of hMSCs is accompanied by the formation of lipid vacuoles 
(Cai, Nakamoto, Hoshiba, Kawazoe, & Chen, 2014). These are formed by accumulation of 
intracellular droplets of triglycerides and can be used as a marker of adipogenic 
differentiation. To identify lipid vacuoles generated in hMSCs following storage, the 
AdiporeRed assay (LONZA) was performed. The assay is based on nile red which 
fluorescences in the presence of droplets of triglyceride. Following adipogenic differentiation 
as described in 4.1.5, culture medium was removed and 1 ml of pre-warmed PBS was added 
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to each well. Lipidic vacuoles were stained by adding 200 l of AdipoRed reagent and 
incubated for 10 minutes, according to manufacturer instructions. Lipidic vacuoles (in red) 
were visualized by fluorescence microscopy (Zeiss Axio Imager II microscope) (excitation 
485 nm; emission 535 nm) and counted by IMARIS software (BITPLANE, 
http://www.bitplane.com/).  
 
 
 
 
4.1.9 Gene expression analysis from micropellets and hMSCs 
 
RNA was extracted via the Trizol/chloroform method from micropellets as described in 
chapter 2.1.7. From cells seeded in T25 flasks, the following modifications were applied: the 
amount of Trizol, chlorophorm, isoprophanol and 75 % ethanol-25 % DEPC-treated water 
used were 1 ml, 200 l, 500 l, 1 ml. cDNA was synthesised as described in 2.1.8.1 and 
quantitative real-time PCR performed as described in 2.1.8.2 using the primers shown in table 
4.8. 
Table 4.8 Primers used for quantitative real-time PCR 
Gene Primer type Sequence (5’-3’) 
GAPDH Forward  ACATCGCTCAGACACCATG 
Reverse  TGTAGTTGAGGTCAATGAAGGG 
Probe  AAGGTCGGAGTCAACGGATTTGGTC 
HPRT1 Forward  TGCTGAGGATTTGGAAAGGG 
Reverse  ACAGAGGGCTACAATGTGATG 
Probe  AGGACTGAACGTCTTGCTCGAGATG 
18s Forward  CGAATGGCTCATTAAATCAGTTATGG 
Reverse  TATTAGCTCTAGAATTACCACAGTTATCC 
Probe  TCCTTTGGTCGCTCGCTCCTCTCCC 
COL2A1 Forward  ACCTTCATGGCGTCCAAG 
Reverse  AACCAGATTGAGAGCATCCG 
Probe  AGACCTGAAACTCTGCCACCCTG 
ACAN Forward  TGTGGGACTGAAGTTCTTGG 
Reverse  AGCGAGTTGTCATGGTCTG 
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Probe  CTGGGTTTTCGTGACTCTGAGGGT 
COL1A1 Forward  CCCCTGGAAAGAATGGAGATG 
Reverse  TCCAAACCACTGAAACCTCTG 
Probe  TTCCGGGCAATCCTCGAGCA 
RUNX2 Forward  TGTTTGATGCCATAGTCCCTC 
Reverse  AATGGTTAATCTCCGCAGGTC 
Probe  CTGTTGGTCTCGGTGGCTGGTAG 
ALPL Forward  GACCCTTGACCCCCACAAT 
Reverse  GCTCGTACTGCATGTCCCCT 
Probe  TGGACTACCTATTGGGTCTCTTCGAGCCA 
PPARG Forward  GAGCCCAAGTTTGAGTTTGC 
Reverse  GCAGGTTGTCTTGAATGTCTTC 
Probe  CGCCCAGGTTTGCTGAATGTGAAG  
FABP4 Forward  CATGTGCAGAAATGGGATGG 
Reverse  AACTTCAGTCCAGGTCAACG 
Probe  CGCCCAGGTTTGCTGAATGTGAAG 
 
 
4.1.10 Factorial design of experiment for hMSCs storage 
 
A full factorial two factor with two level design (22 ) was implemented to study the effect of 
temperature and oxygen tension on the hMSCs chondrogenic, osteogenic and adipogenic 
potential as well as metabolism over 5 day storage. For each factor, two levels (high and low) 
were selected, namely 26 °C and 37 °C for temperature and 3 % and 20 % for oxygen. The 
experiment was repeated for three healthy donors. One nuisance factor was introduced to 
account for the inter donor variability. Response variables were selected on the basis of the 
biological property under investigation for the hMSCs and are listed in Table 4.8. Each 
response was an average value of triplicated measurements. JMP SAS software 
(http://www.jmp.com/en_gm/home.html ) was used for all statistical analysis and data 
transformation. ANOVA was used to identify main effects and interaction between factors.  
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Table 4.8 Input and output variables for the hMSCs storage system. Input and output variables 
of the full factorial design of experiments are presented.  
Input variables Output variables 
Temperature 
Oxygen 
Glucose 
Lactate  
Glutamine 
Ammonia 
COL2A1 
ACAN 
COL1A1 
RUNX2 
ALPL 
PPARG
FABP4 
 
To further investigate the osteogenic and adipogenic potential of hMSCs following storage, 
one additional full factorial 22 design of experiment was created with data from just one 
donor. Input variables were temperature and oxygen while output variables were ALP 
activity and number of adipocytes.  
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4.2 Results  
 
 
4.2.1 Post storage metabolites concentration for undifferentiated hMSCs  
 
The concentrations of glucose, lactate, glutamine and ammonia in spent medium were 
measured following 5 day storage in T25 flasks as described in table 4.1. This permitted the 
evaluation of the effect of temperature and oxygen on the modulation of hMSCs metabolism 
and for the identification of the storage conditions which might be detrimental to hMSCs 
biological properties.  
When stored at 20 % oxygen and 37 °C, 94 % of glucose available was metabolized (Fig. 
4.3).  
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Fig. 4.3 Post-storage glucose concentrations (g/l) in spent medium for hMSCs seeded and stored 
in T25 flasks. hMSCs were isolated from three healthy donors and exposed to storage conditions 
listed in Table 4.1. Dashed line represents initial glucose concentration (i.g.c.)(1 g/l). Each 
measurement requires 1 ml of spent medium. Values are plotted as mean and standard error of 
the mean (n=3) for three technical replicates. For each storage condition, donors average 
represents the mean value of glucose concentration post storage for the three donors. (37 C= 
37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
 
 
 
This decreased to 33 % when the temperature was lowered to 26 °C while maintaining the 
same oxygen tension. For storage at 3 % oxygen, glucose consumption slightly increased to 
96 % at 37 °C and 35 % at 26 °C. This might be explained by the increased proliferation 
which has been demonstrated by Dos Santos et al. (dos Santos et al., 2009) when hMSCs are 
cultured under hypoxia. Temperature has a statistically significant effect on glucose 
concentration after 5 day storage for all three donors (p=0.03). hMSCs from the three donors 
behaved in a consistent manner.  
Consistently with glucose metabolism, storage at higher temperature (37 °C) increased the 
release of lactate at both oxygen tension levels (20 % and 3 %) (Fig.  4.4). 
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Fig. 4.4 Post-storage lactate concentrations (g/l) in spent medium for hMSCs seeded and stored 
in T25 flasks. hMSCs were isolated from three healthy donors and exposed to storage conditions 
listed in Table 4.1. Each measurement requires 1 ml of spent medium. Values are plotted as 
mean and standard error of the mean (n=3) for three technical replicates. For each storage 
condition, donors average represents the mean value of lactate concentration post storage for 
the three donors. (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
 
 
 
 
When stored at 3 % oxygen tension level, lactate released reached 1 g/l at 37 °C and 0.3 g/l at 
26 °C. Decreasing storage temperature from 37 to 26 °C led to a 63 % decrease in lactate. 
This effect was reduced for storage at 20 % oxygen tension level, where lactate release 
decreased from 0.87 g/l at 37 °C to 0.34 g/l at 26 °C (61 % reduction). Temperature has a 
statistically significant effect on lactate concentration after 5 day storage for the three donors 
(p=0.02). 
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It is important to note that the lactate inhibitory concentration of 3.15 g/l identified by Schop 
et al (Schop et al., 2009) was not reached in any of the storage conditions following 5 day 
storage.  
Glutamine metabolism was limited to 8.9 % of the initial glutamine concentration (3.1 mM) 
for both oxygen tension levels when the cells where stored at 26 °C (Fig.4.5). 
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Fig. 4.5 Post-storage glutamine concentrations (mM) in spent medium for hMSCs seeded and 
stored in T25 flasks. hMSCs were isolated from three healthy donors and exposed to storage 
conditions listed in Table 4.1. Dashed line represents initial glutamine concentration (i.g.c.) (3.1 
mM). Each measurement requires 1 ml of spent medium. Values are plotted as mean and 
standard error of the mean (n=3) for three technical replicates. For each storage condition, 
donors average represents the mean value of glucose concentration post storage for the three 
donors. (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
 
 
 
161 
 
At 37 °C, glutamine metabolism was considerably higher (63.44 % and 52.93 % for 20 and 3 
% oxygen tension levels respectively). Temperature and oxygen (and their interaction) did 
not have a statistically significant effect on glutamine concentration after 5 day storage.  
Consistently with glutamine metabolism, concentration of NH3 when the cells were stored at 
26 °C was 0.8 mM for both oxygen tension levels (Fig. 4.6). 
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Fig. 4.6 Post-storage NH3 concentrations (mM) in spent medium for hMSCs seeded and stored 
in T25 flasks. hMSCs were isolated from three healthy donors and exposed to storage conditions 
listed in Table 4.1. Each measurement requires 1 ml of spent medium. Values are plotted as 
mean and standard error of the mean (n=3) for three technical replicates. For each storage 
condition, donors average represents the mean value of glucose concentration post storage for 
the three donors. (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
 
 
Storage at 37 °C led to an increase in NH3 of 62.72 % and 51.23 % for 20% oxygen and 3 % 
oxygen respectively. Temperature and oxygen (and their interaction) did not have a 
statistically significant effect on NH3
 concentration after 5 day storage. 
It was important to note that ammonia reached the inhibitory concentration value of 2.4 mM 
defined by Shop et al.(Schop et al., 2009) only for donor #1 when the cells were stored at 
37°C and 20 % oxygen. This result was consistent with what Dos Santos et al. demonstrated 
for hMSCs cultured under normoxia (20 % O2) (dos Santos et al., 2009).  
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4.2.2 Post storage chondrogenic differentiation of hMSC in micropellets 
 
The chondrogenic differentiation potential of the hMSCs following storage was evaluated by 
gene expression and GAG quantification in micropellets as described in 4.1.2.  Only when 
stored at 37 °C and 20 % oxygen, did hMSCs retain the ability to differentiate into 
chondrocytes (Fig. 4.7). In all other storage conditions, COL2A1 was down regulated. All 
three donors showed consistent trends.  
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Fig. 4.7 Fold change in COL2A1 gene expression in response to storage. hMSCs isolated from 
three healthy donors and exposed to storage conditions listed in Table 4.1. Fold changes values 
are relative to non-stored hMSCs (day 0) and are plotted as mean and standard error of the 
mean for three technical replicates for each donor. The average fold change values for the three 
healthy donors is also plotted for each storage condition. Data on y-axis are on logarithmic scale 
(log10). (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5).  
 
 
Reduced oxygen tension and reduced temperature led to lower COL2A1 expression compared 
to micropellets from non-stored hMSCs. While storage at 37 °C and 20 % oxygen 
corresponded to the highest COL2A1 expression, storage at 26 °C and 3 % oxygen 
corresponded to the lowest. Temperature and oxygen and their interaction did not have a 
statistical significant effect on COL2A1 expression.  
Unlike COL2A1, ACAN was upregulated in all storage conditions for donor #1 and #3 
(Fig.4.8).  
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Fig. 4.8 Fold change in ACAN gene expression in response to storage. hMSCs isolated from 
three healthy donors and exposed to storage conditions listed in Table 4.1. Fold changes values 
are relative to non-stored hMSCs (day 0) and are plotted as mean and standard error of the 
mean for three technical replicates for each donor. The average fold change values for the three 
healthy donors is also plotted for each storage condition. Data on y-axis are on logarithmic scale 
(log10). (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
 
 
Donor #2 showed rather limited variations in ACAN expression compared to micropellets 
from untreated (non-stored) hMSCs in all storage conditions. hMSCs exposed to 5 day 
storage at 37 °C and 3 % oxygen showed the highest ACAN expression. Increase in storage 
temperature or decrease in oxygen tension led to higher ACAN expression. Temperature and 
oxygen and their interaction did not have a statistical significant effect on ACAN expression. 
COL1A1, which encodes for the 1 polypeptide chain of type 1 collagen, was not 
overexpressed for micropellets from hMSCs exposed to 5 day storage at 37 °C and 20 % 
oxygen (Fig.4.9). 
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Fig. 4.9 Fold change in COL1A1 gene expression in response to storage. hMSCs isolated from 
three healthy donors and exposed to storage conditions listed in Table 4.1. Fold changes values 
are relative to non-stored hMSCs (day 0) and are plotted as mean and standard error of the 
mean for three technical replicates for each donor. The average fold change values for the three 
healthy donors is also plotted for each storage condition. Data on y-axis are on logarithmic scale 
(log10). (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
 
 
 
For those cells, the storage did not inhibit but rather enhanced chondrogenesis leading to 
COL2A1 upregulation (Fig 4.7). Consistently, COL1A1 was downregulated.  In all other 
storage conditions, COL1A1 was considerably overexpressed and this correlates with 
COL2A1 downregulation.  
Temperature has a significant effect on COL1A1 expression (p=0.0055). Oxygen did not have 
a statistically significant effect while the interaction with temperature was statistically 
significant (p=0.0016). This means that changes in COL1A1 expression due to oxygen will be 
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dependent on the temperature level. The effect of oxygen on COL1A1 was remarkably greater 
when the hMSCs were stored at 37 °C than at 26 °C. 
Sulfated glycosaminoglycan (sGAG) synthesis and accumulation in pellets has been 
considered as a marker of chondrogenesis for hMSCs (Mackay et al., 1998). The assay used 
to measure GAGs was based on 1,9-dimethylmethylen blue which binds to the sulphated 
polysaccharide component of proteoglycans. hMSCs stored for 5 days at 37 °C and 20 % 
oxygen showed the greatest accumulation of sGAG relative to micropellets from non-stored 
hMSCs (Fig.4.10). 
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Fig. 4.10 Post storage GAGs accumulations in micropellets. hMSCs isolated from three healthy 
donors and exposed to storage conditions listed in Table 4.1. Fold changes values are relative to 
non-stored hMSCs (day 0) and are plotted as mean and standard error of the mean for three 
technical replicates for each donor. The average fold change values for the three healthy donors 
is also plotted for each storage condition. Data on y-axis are on logarithmic scale (log10). (37 C= 
37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
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Lower temperature and oxygen tension level reduced the amount of sGAGs accumulated 
during the 14 day differentiation phase. Adesina et al. showed that hMSCs undergo a more 
robust chondrogenesis when differentiated under hypoxic conditions  (Adesida, Mulet-Sierra, 
& Jomha, 2012). However, little to no evidence is available from others regarding the effect 
of hypoxia, alone or in combination with temperature, on hMSCs prior to a standard 
differentiation protocol under normoxia.  
 
 
 
 
 
4.2.3 Post storage osteogenic differentiation of hMSC 
 
The osteogenic differentiation potential of the hMSCs following storage was evaluated by 
gene expression using hMSCs stored in T25 flasks and ALP activity assay using cells stored 
in 24 well plates.  
RUNX2, which encodes for runt related transcription factor 2 and which is required for bone 
formation, was upregulated in all storage conditions for donor #1 and donor 3 (Fig.4.11). For 
all three donors, RUNX2 expression increased as temperature decreased from 37 °C to 26 °C, 
while no changes can be noticed due to oxygen level changes.  
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Fig. 4.11 Fold change in RUNX2 gene expression in response to storage. hMSCs isolated from 
three healthy donors and exposed to storage conditions listed in Table 4.1. Fold changes values 
are relative to non-stored hMSCs (day 0) and are plotted as mean and standard error of the 
mean for three technical replicates for each donor. The average fold change values for the three 
healthy donors is also plotted for each storage condition. Data on y-axis are on logarithmic scale 
(log10). (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
 
 
ALPL, which encodes for the tissue non-specific form of the enzyme alkaline phosphatase 
(ALP), showed a similar trend to RUNX2 (Fig. 4.12). ALPL expression slightly increased 
when temperature decreased for donor #1 and #3. When stored at 26 °C, hMSCs from donor 
#2 and #3 showed a slight increase in ALPL expression as oxygen tension decreased from 20 
to 3 %.  
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Fig. 4.12 Fold change in ALPL gene expression in response to storage. hMSCs isolated from 
three healthy donors and exposed to storage conditions listed in Table 4.1. Fold changes values 
are relative to non-stored hMSCs (day 0) and are plotted as mean and standard error of the 
mean for three technical replicates for each donor. The average fold change values for the three 
healthy donors are also plotted for each storage condition. Data on y-axis are on logarithmic 
scale (log10). (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
 
 
In order to further investigate the effect of temperature and oxygen on the osteogenic 
differentiation potential, hMSCs from one donor (donor #1) were also seeded, stored and 
differentiated in 24 well plates. ALP enzymatic activity was assessed by pNPP assay as 
described in 4.1.7 at day 14 of osteogenic differentiation. ALP is a known marker of 
osteoblastic differentiation (Sheehy, Buckley, & Kelly, 2012). Cells stored at lower 
temperature and lower oxygen levels showed higher ALP activity (Fig. 4.13). The effect of 
temperature was statistically significant for all the three donors (p=0.023).   
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Following the pNPP assay, the cells were stained using Fast blue staining as described in 
4.17. ALP stained cells showed a purple colour (Fig.4.14).  
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Fig. 4.13 Post storage ALP activity of hMSCs differentiated into osteogenic lineage.  The ALP 
activity was measured with the pNPP assay and expressed relative to the ALP activity of 
differentiated non-stored hMSCs (day 0). hMSCs for one representative donor were used for 
this experiments. Data are expressed as mean and standard error of the mean for three 
biological replicates. (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
 
 
ALP staining was highest at the lower temperature and oxygen levels. Compared to non 
stored differentiated hMSCs, ALP staining was lower for 5 day storage at 37 °C and 20 % 
oxygen. This result suggests a detrimental effect of temperature and oxygen on the osteogenic 
potential of hMSCs. Differences in ALP staining were also found for storage at different 
oxygen levels; lower oxygen level corresponds to higher ALP staining both at 37 °C and 26 
°C storage. 
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Fig. 4.14 ALP staining of differentiated hMSCs following 5 day storage. hMSCs from the donor 
were differentiated towards osteogenic lineage for 14 days before performing the ALP assay and 
staining using a Fast blue salt. Representative field of views are shown for all four storage 
conditions (Table 4.1) in a matrix format (oxygen versus temperature). Representative field of 
view of differentiated non-stored hMSCs is also shown (top). ALP positively stained cells are 
shown in purple. (Scale bar = 100 m). 
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4.2.4 Post storage adipogenic differentiation of hMSC 
 
The adipogenic differentiation potential of the hMSCs following storage was evaluated by 
gene expression using hMSCs stored in T25 flasks and lipid vacuole quantification using 
hMSCs stored in plates as described in 4.1.8. 
PPARG, which encodes for the peroxisome proliferator-activated receptor gamma linked to 
increased lipid uptake, and FABP4, which encodes for fatty acid binging protein 4, have been 
widely used as markers for adipogenic differentiation (Basciano et al., 2011). PPARG was 
upregulated in all four storage conditions for all three donors compared to non-stored cells 
(Fig. 4.15). Higher PPARGexpression was linked to lower storage temperature and higher 
oxygen level.   
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Fig. 4.15 Fold change in PPAR gene expression in response to storage. hMSCs isolated from 
three healthy donors and exposed to storage conditions listed in Table 4.1. Fold changes values 
are relative to non-stored hMSCs (day 0) and are plotted as mean and standard error of the 
mean for three technical replicates for each donor. The average fold change values for the three 
healthy donors are also plotted for each storage condition. Data on y-axis are on logarithmic 
scale (log10). (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
 
 
FABP4 was also upregulated for all storage conditions for all three donors (Fig. 4.16). Higher 
storage temperature and higher oxygen level were linked to higher expression of FABP4. The 
effect of temperature was statistically significant for all three donors (p=0.0032). 
In order to further investigate the effect of temperature and oxygen on the adipogenic 
differentiation potential, hMSCs from one representative donor (donor #3) were also seeded, 
stored and differentiated in 24 well plates. The presence of lipid vacuoles was assesed using 
AdipoRED staining (Lonza). Results are shown in Fig. 4.17. The number of adipocytes per 
field was quantified via imaging analysis using IMARIS software (www.bitplane.com). The 
highest number of adipocytes was observed for cells stored at 26 °C and 20 % oxygen, while 
storage at 37 °C led to a reduction in number compared to differentiated non-stored cells 
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(Fig.4.18). The effect of temperature on the number of adipocytes was statistically significant 
(p=0.0038).    
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Fig. 4.16 Fold change in FABP4 gene expression in response to storage. hMSCs isolated from 
three healthy donors and exposed to storage conditions listed in Table 4.1. Fold changes values 
are relative to non-stored hMSCs (day 0) and are plotted as mean and standard error of the 
mean for three technical replicates for each donor. The average fold change values for the three 
healthy donors are also plotted for each storage condition. Data on y-axis are on logarithmic 
scale (log10). (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= day 5). 
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Fig. 4.17 AdipoRed staining of adipocytes following 5 day storage. hMSCs from one healthy 
donor were differentiated towards adipogenic lineage for 14 days before being stained using 
AdipoRed staining (Lonza). AdipoRed positive cells represent adipocytes (in red) and were 
visualized by fluorescence microscopy (Zeiss Axio Imager II microscope) (excitation 485 nm; 
emission 535 nm). Representative fields of stained adipocytes are shown for all four storage 
conditions (Table 4.1) in a matrix format (oxygen versus temperature). Representative field of 
differentiated non-stored hMSCs is also shown (top). (Scale bar = 150 m). 
 
 
177 
 
 
 
 
3
7
 C
 2
0
%
 O
2
 D
5
3
7
C
  
3
%
 O
2
 D
5
2
6
C
 2
0
%
 O
2
 D
5
2
6
C
 3
%
 O
2
 D
5
0
5
1 0
1 5
S to ra g e  C o n d itio n s
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 n
o
n
 s
to
r
e
d
 c
e
ll
s
D o n o r  # 1
1
A d ip o R e d  p o s it iv e
a d ip o c y te s
 
Fig. 4.18 Number of adipocytes for differentiated hMSCs following 5 day storage. Adipocytes 
were stained using the AdipoRed staining (Lonza),visualized by fluorescence microscopy (Zeiss 
Axio Imager II microscope) (excitation 485 nm; emission 535 nm) and counted by IMARIS 
software (BITPLANE, http://www.bitplane.com/). For each storage condition, three fields were 
taken for each of the three culture wells. The number of adipocytes has been calculated as the 
average of the three culture wells for each storage condition relative to differentiated hMSCs 
which were not exposed to any storage condition. (37 C= 37 ̊C, O2= pO2, oxygen tension, D5= 
day 5). Dashed line represents fold change equal to 1 (no change in number of adipocytes 
compared to not stored cells.) 
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4.3 Brief summary of data described  
 
In this chapter, the storage of hMSCs from three healthy donors has been studied. Table 4.9 
summarizes the key findings. 
Table 4.9 Brief summary of key findings for the storage of hMSCs in a controlled environment 
for 5 days. 
 Key finding  
Metabolites 
Glucose Glucose concentration in spent medium increased as storage temperature 
decreased from 37 to 26 °C. The effect of temperature on glucose 
concentration was statistically significant.  
Lactate  Lactate concentration increased as storage temperature increased from 26 
to 37 °C. Lactate did not reach the inhibitory concentration of 3.15 g/l in 
any of the storage conditions.  
Glutamine Glutamine concentration was higher at lower temperature. Oxygen level 
only slightly affected glutamine concentration.  
Ammonia Ammonia concentration was higher for higher storage temperature. 
Ammonia concentration reached its inhibitory concentration 2.4 mM for 
donor 1 at 37 °C and 20 % oxygen. 
Chondrogenic potential 
COL2A1 COL2A1 was down regulated for all storage conditions except for  37 °C 
and 20 % O2. 
ACAN ACAN was upregulated in all storage conditions for donor 1, while for 
donor 3 it was down regulated only for storage at 26 C and 3 % oxygen.  
COL1A1 Lower storage temperature and lower oxygen tension lead to upregulation 
of COL1A1. For storage at 37 °C and 20 % oxygen, COL1A1 was not 
upregulated. The effect of temperature and its interaction with oxygen 
levels were statistically significant. 
GAGs/DNA Lower temperature and oxygen tension level reduced the amount of 
sGAGs accumulated during the 14 day differentiation phase. 
Osteogenic potential 
RUNX2  RUNX2 expression increased as temperature decreased from 37 to 26 °C 
while no changes occurred due to oxygen level. 
ALPL Temperature and oxygen did not significantly affect ALPL expression.  
ALP activity  ALP staining was higher at lower temperature and oxygen levels. The 
effect of temperature on ALP activity was statistically significant. 
Adipogenic potential 
PPARG  PPARG was upregulated in all storage conditions. Higher expression was 
linked to lower storage temperature and higher oxygen levels. 
FABP4 FABP4 was upregulated for all storage conditions for all three donors. 
The effect of temperature was statistically significant.  
adipocytes The number of adipocytes was significantly higher following storage at 
26 °C and 20 % oxygen. 
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4.4 Discussion 
 
The aim of this chapter was to investigate the storage properties of hMSCs. The combined 
effect of temperature and oxygen over 5 day storage was studied.  
The need for better cell product characterization to improve the manufacturing of cell therapy 
medicinal products has been highlighted  (Bravery et al., 2013). This should include a deeper 
understanding of how process parameters, such as temperature and oxygen, affect the 
biological properties of the cells. This is even more important for the effective design of 
storage and transportation steps as these normally rely on passive containers where such 
parameters cannot be tightly controlled (PDA technical report 72). 
In the undifferentiated hMSCs, temperature was the main factor affecting glucose, lactate, 
glutamine and ammonia metabolism. Unlike for the storage of cartilage discs, the effect of 
oxygen on ammonia metabolism was not statistically significant. However, hMSCs from 
donor#1 reached the reference inhibitory value for ammonia defined by Shop et al. (Schop et 
al., 2009) when stored at 37 °C and 20 % O2 for 5 days.  
A number of research groups have investigated the effect of low oxygen tension (hypoxia) on 
hMSCs differentiation potential, with emphasis on the effect that this has during the 
chondrogenic, osteogenic or adipogenic differentiation process (Markway et al., n.d.) 
(Malladi, Xu, Chiou, Giaccia, & Longaker, 2006)(Buravkova, Andreeva, Gogvadze, & 
Zhivotovsky, 2014).  In this study, hMSCs have been exposed to four different combinations 
180 
 
of oxygen and temperature prior to the differentiation process, which more closely resembles 
the stimulation cells undergo during storage and transportation.  
Storage of hMSCs at 37 °C and 20 % O2 for 5 days increased the expression of COL2A1 
while reducing the expression of COL1A1. This suggests a greater chondrogenic potential 
which was not present for the other storage conditions. The amount of GAGs accumulated 
over the 14 days storage period was also higher for this storage condition. This demonstrates 
that when hMSCs are exposed to temperature and oxygen levels that move away from 37 °C 
and 20 % O2 for 5 days, their chondrogenic potential is impaired. This might appear in 
contrast with the fact that during embryonic development, pluripotent stem cells differentiate 
into chondrocytes and form cartilage in a hypoxic environment (Adesida et al., 2012). 
However, the difference might lay on the different role that hypoxia play during and prior to 
the differentiation process. 
The osteogenic potential of the hMSCs from the three donors was not significantly affected 
by 5 day storage under the different combinations of temperature and oxygen. However, for 
donor#1, the effect of temperature was statistically significant and ALP activity reached its 
highest for hMSCs exposed to 5 day storage at 26 °C and 3 % oxygen. In a recent study, 
Sheehy at al. demonstrated that hypoxia pre-conditioning at 37 °C inhibits osteogenic 
differentiation (Sheehy et al., 2012). However, results described in this chapter demonstrate 
the effect of temperature on the osteogenic potential is even greater.  
The 5 day storage led to upregulation of the adipogenic markers, such as PPARGand FABP4 
for all three donors. The effect of temperature was significant on FABP4 regulation. Lower 
storage temperature increased the adipogenic potential of hMSCs and this was confirmed by 
the AdipoRed staining. The detrimental effect of hypoxia on the adipogenic and osteogenic 
potential of hMSCs has been documented (Hung et al., 2007). Results described in this 
181 
 
chapter showed that storage at a lower temperature (26 °C) remarkably increases their 
adipogenic potential. The significance of this key finding is not just limited to storage and 
transportation of hMSCs but could be used for the expansion of adipose derived human stem 
cells (hASCs) which are currently been investigated for a number of clinical applications, 
including but not limited to wound healing. (Keung et al., 2013)(clinicaltrials.gov). 
Similarly to what was described in chapters 2 and 3 for the storage of cartilage discs, storage 
conditions should be defined depending on the biological property that needs to be preserved.  
Temperature and oxygen can be adequately selected to modulate chondrogenic, osteogenic 
and adipogenic potential of hMSCs. The selection of higher or lower values of these two 
parameters will depend upon the therapeutic applications the hMSCs are intended for as 
discussed in chapter 5.  
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Chapter 5  
 
General discussion  
 
The use of human cells as medicinal products has generated a great deal of interest 
worldwide for the potential to treat a broad range of high impact unmet clinical needs 
(Heathman et al., 2015). However, the ‘living’ nature of such products creates a number of 
challenges that are new to the biopharmaceutical community. The ability to ‘manufacture, 
store, transport and distribute regenerative medicine products’ has been identified by the 
UK’s Office for Life Science as a necessary step in order for these therapies to join 
‘mainstream clinical practice’. 
(https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/32459/11-
1056-taking-stock-of-regenerative-medicine.pdf )  
As there is convincing evidence that cells are responsive to oxygen concentration within the 
growth medium, it is important to investigate its effect in combination with temperature.   
The work described in this thesis aimed to investigate a novel temperature range (26-37 ⁰C) 
for storage and transportation and, for the first time, to combine temperature with a variable 
oxygen tension over a simulated shelf life of 5 or 7 days.  
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5.1 Key findings 
 
5.1.1 Post storage viability  
 
For cell based medicinal product, viability can be considered as one important indicator to 
assess the stability over the shelf life. Although many assays are currently available (Ng et 
al., 2005), the assessment of viability can pose technical challenges when cells are organized 
into tissue. In such situations, metabolic dyes such as Alamar blue can provide an indicator of 
overall metabolic activity of the population of cells within the construct. The main limitation 
of metabolic assays, including Alamar blue, is that cellular metabolic activity varies greatly 
throughout the lifecycle of cells (Rampersad, 2012). On the other hand, alternative viability 
measurements which assess viability by monitoring cell membrane integrity could not be 
applied for cartilage discs as the cells could not be consistently isolated without altering their 
viability. 
Viability of cartilage discs following storage in a controlled environment was tested using the 
Alamar blue assay as described in chapter 2. For all three donors, storage at 26 ⁰C led to a 
better viability than storage at 37 ⁰C after both 5 and 7 days. Oxygen tension did not have a 
large effect on modulating viability post-storage. Viability decreased over time but was on 
average no lower than 75.5 % even after 7 day storage at 37 ⁰C and 20 % oxygen. As already 
noted, there are limited data on the storage of hMSCs at body temperature for 7 days. 
However, other groups have investigated the viability of stem cells in a slightly different but 
related context. For example, Alves and colleagues also demonstrated that human pluripotent 
stem cell-derived cardiomyocytes (hPSC-CMs) showed high cell recovery (>70%) when 
stored for 7 days, although the cells were stored at 4 °C and with a clinical-compatible 
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preservation formulation (Serra, Brito, Correia, & Alves, 2012). Interestingly, hPSC-CM 
recovery was higher in three-dimesional aggregates than in 2D monolayers (Correia et al., 
2016). While aggregation of therapeutic proteins is one the most dangerous aspects of 
protein-based drugs (Chirino, Ary, & Marshall, 2004), for cell-based medicinal products this 
might provide a more physiological environment, enhancing their preservation over time. 
Interestingly, Bayouseff et al. recently demonstrated that aggregation of C2C12 myoblast 
cells maintained higher viability compared to single cells in suspension. (Bayoussef et al., 
2012)  
On the other hand, Patricia Gálvez-Martín and co-workers showed that the viability of 
adipose derived-hMSCs was maintained above 80 % for 48 hours storage at 4 °C but 
drastically decreased when the cells where stored at 25 °C and 37 °C (Galvez-Martin, 
Hmadcha, Soria, Calpena-Campmany, & Clares-Naveros, 2014) .  
The ECM the cells are embedded in might also exert a protective effect while contributing to 
the proliferation of cells when lost which is not normally the case for cells stored in 
suspension. This ‘protective’ effect can also be created by encapsulating the cells into 
alginate, as recently demonstrated by Swioklo et al. (2015) for adiposed derived 
mesenchymal stem cells and by Mahler and co-workers for hepatocytes (Mahler et al., 2003). 
However, as discussed in chapter 2, the length of the shelf-life might also be dependent on 
the cell type as for commercially available engineered tissue products this varies from 36 
hours for Holoclar to 15 days for Apligraph. 
Therefore, for some cell types, aggregation and the presence of ECM enable longer shelf life 
even when the product is stored at temperatures closer to 37 °C. 
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5.1.2 Metabolites 
 
When cells are stored at a temperature above -150 °C, they will continue to metabolize 
glucose and glutamine while producing lactate and ammonia as waste products (Schop et al., 
2009). 
As part of more complex formulation studies, it is important to evaluate that the amount of 
glucose and glutamine available is sufficient to allow the cells to survive while lactate and 
ammonia do not reach or exceed values which might have a detrimental effect. 
Chapters 2 and 3 demonstrated that the multifactorial approach can be used to identify 
temperature and oxygen as variables that can be engineered to modulate specific metabolic 
pathway during storage.  
For cartilage discs, a decrease in storage temperature from 37 ⁰C to 26 ⁰C led to 34 % less 
glucose metabolized following 5 day storage while lactate release was 87% lower.  
Lower oxygen tension had less of an effect on the amount of glucose and lactate. Even after 7 
days storage, lower oxygen resulted in only a 4 % decrease of lactate release. Lactate release 
inversely matched glucose consumption with higher values for longer storage at higher 
temperature. Moreover, oxygen and temperature interaction showed a statistically significant 
effect on lactate metabolism. This implies that the temperature mediated decrease in lactate 
released in the medium will be dependent on the oxygen tension present in the medium.  
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For hMSC storage, lower temperature led to 61 % less glucose metabolized and 63 % less 
lactate released.  
Storage at lower temperature and low oxygen condition also reduced glutamine metabolism. 
For cartilage discs, glutamine concentration in the spent medium post-storage ranged from 
1% of the initial glutamine concentration (2 mM) after 5 day storage at 37 ⁰C and 20 % 
oxygen to 76 % after 5 day storage at 26 ⁰C and 3 % oxygen. Consequently, a lower amount 
of ammonia is produced after both 5 and 7 day storage. Interestingly, oxygen had a 
statistically significant effect on glutamine and ammonia concentration in the spent medium 
(along with storage temperature and length) for cartilage discs. This suggests that temperature 
and oxygen could be used to modulate the amount of waste products released, products that 
might have a detrimental effect on the cells.  
However, for undifferentiated hMSC storage, glutamine and ammonia metabolism was less 
strongly influenced by oxygen tension, suggesting that the metabolic preferential pathway of 
undifferentiated hMSCs is different compared to the hMSC-derived chondrocytes. This was 
also demonstrated by Pattappa and co-workers (Pattappa, Heywood, de Bruijn, & Lee, 2011). 
A limited number of studies have investigated the energy metabolism of MSCs with the aim 
to better understand it and improve growth conditions and cell yield for therapeutic 
applications. In an attempt to mimic more closely the bone microenvironment, with oxygen 
tension which varies from 1- 6 %, the effect of hypoxia on proliferation has been reported 
(Grayson, Zhao, Bunnell, & Ma, 2007b). Dos Santos et al. demonstrated that when cultured 
under low oxygen condition (2%), cells metabolized more glucose and glutamine but released 
lower quantities of lactate and ammonia (Dos Santos et al., 2010). The higher consumption of 
glucose was correlated to higher proliferation under hypoxia. This result was in contrast with 
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that reported by Schop et al (2009), who reported a lower glucose consumption rate for 
hMSCs cultured under low oxygen conditions (3%) on microcarriers (Schop et al., 2009). 
Moreover, higher rate of glutamine consumption for the first 5 days of culture under hypoxia 
was not correlated to higher ammonia accumulation (Dos Santos et al., 2010), unlike what 
was found for cartilage discs (chapter 2) and undifferentiated hMSCs (chapter 4) in this 
thesis.  
There is increasing evidence that metabolic pathways are strongly dependent on the 
proliferating state and cell type. Varum et al. (2011) demonstrated that iPSCs and hESCs, 
which are characterized by a high proliferating rate, mainly rely on glycolysis to meet their 
energy demand (Varum et al., 2011). Osteoblasts, with lower proliferative capacity compared 
to pluripotent stem cells, demonstrated the ability to alternate both glycoslysis and oxidative 
phosphorylation for their ATP production (Komarova et al., 2000).  
This suggests that glucose consumption and ammonia built-up in the final formulation should 
be evaluated for each cell-based product.  
 
5.1.3 Chondrogenic potential 
 
hMSCs have also been investigated for their potential to regenerate hyaline cartilage (Steinert 
et al., 2012). Because of the low engraftment rate of the cells in situ, these are often 
embedded in hydrogel matrix and can be applied or even directly injected into the knee 
(Spiller et al., 2011). The immunogenicity of allogeneic hMSCs have been investigated 
(Consentius et al., 2015). In a recent study, Nathalie Rouas-Freiss and co-workers 
demonstrated that hMSCs from bone marrow and adipose tissue maintained their 
188 
 
immunosuppressive properties even after chondrogenesis (Du et al., 2016). As chondrogenic 
differentiation potential is key, it is important to assess how temperature and oxygen can 
modulate this potential during storage. 
Lower temperature and higher oxygen tension correspond to higher COL2A1 fold change 
relative to non-stored cartilage discs following 5 and 7 day storage. As mentioned in chapter 
2, this could be linked to in-vivo cartilage homeostasis. However, in these storage conditions 
(26 °C/20 % oxygen for 5 and 7 days storage), COL1A1 was upregulated. 
The effect of temperature and oxygen was also studied on undifferentiated hMSCs.  Different 
trends were observed when investigating the effect of temperature and oxygen on hMSCs 
prior to chondrogenic differentiation. Unlike cartilage discs, COL2A1 expression was highest 
following 5 day storage at higher temperature and higher oxygen (37 °C and 20 % oxygen). 
Only in this storage condition was COL2A1 upregulated compared to non-stored hMSCs. 
Consistently with cartilage discs, COL1A1 was downregulated for 37 ⁰C/20 % oxygen 
(preferred condition for COL2A1 expression) and significantly overexpressed for other 
storage conditions. Temperature and its interaction with oxygen were statistically significant. 
This implies that the effect of oxygen in modulating COL1A1 expression will be dependent 
on temperature. Many groups have reported that hypoxia stimulation at 37 °C can increase 
the chondrogenic potential for hMSCs derived from a number of sources, such as bone 
marrow (Khan, Adesida, Tew, Lowe, & Hardingham, 2010), infrapatellar fat pad (Khan et 
al., 2007) , but not for adipose tissue derived hMSCs (Malladi et al., 2006). 
For cartilage discs, storage at high temperature (37 °C) and oxygen (20 %) also led to higher 
ACAN expression both after 5 and 7 day storage. On the other hand, when storing 
undifferentiated hMSCs, ACAN expression was highest at 37 °C and 3 % oxygen for 5 days. 
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This was not confirmed by GAG accumulation, which was highest for storage at 37 °C and 
20 % oxygen. 
This suggests that temperature and oxygen can provide ‘contrasting’ stimuli to the cell 
product during storage, as discussed in chapter 3. As chondrogenesis can occur at both 
normoxic (20 %) and hypoxic (3 %) conditions, it can be hypothesised that some of the effect 
of hypoxia pre-stimulation is ‘lost’ when the cells are exposed again to 20 % oxygen.  
 
 
5.1.4 Osteogenic potential 
 
Although bone has a very high capacity to self-heal, the use of hMSCs for bone regeneration 
have been extensively studied mainly for the treatment of large bone defects or traumatic 
injuries (Steinert et al., 2012). 
hMSCs stored for 5 days retained the potential to differentiate towards the osteogenic lineage 
as demonstrated by RUNX2 and ALPL which were upregulated in all storage conditions.  
Moreover, alkaline phosphatase (ALP) staining was highest at the lower temperature and 
oxygen levels. For both storage temperatures (26 and 37 °C), lower oxygen levels correlated 
to higher ALP staining.  
The effect of hypoxia on hMSC osteogenic potential is controversial (Buravkova et al., 
2014). Differences in culture conditions as well as donor make the comparison of results 
from different research groups difficult. If the effect of hypoxia is studied using a range of 
low oxygen levels (1-5 % oxygen) and variables levels of exposure (2 h to 60 h or more), 
hMSCs show a lower proliferation potential for 1% oxygen for 48 h (Epimenko et al 2011, 
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Hung et al 2007) but a slight increase in duration of incubation to 4 days at 1 % led to an 
enhanced proliferation potential for both umbilical cord and bone marrow derived hMSCs 
(Lavrienteva et al 2010). This suggests that hMSCs might possess a protective mechanism, 
such as an adaptation to low oxygen level, that can be reversed. While there is evidence that 
exposure to hypoxia during differentiation will inhibit osteogenic potential ( Malladi et al. 
2006, Fehrer et al. 2007, D’Ippolito et al. 2006), the data described in this thesis demonstrate 
that this potential can be restored once hMSCs are back to 37 °C and 20 % oxygen.  
Consistent results were also shown by Buravkova and colleagues (Buravkova, 
Grinakovskaya, Andreeva, Zhambalova, & Kozionova, 2009).  
Other studies have demonstrated that the osteogenic potential of hMSCs can be preserved 
following low temperature storage (4 °C) for placenta derived (Pogozhykh, Prokopyuk, 
Pogozhykh, Mueller, et al., 2015) and bone marrow (Ginis, Grinblat, & Shirvan, 2012) 
derived hMSCs. 
 
5.1.5 Adipogenic potential  
 
 
PPARG and FABP4, two commonly used adipogenic gene markers, were also upregulated in 
all hMSCs following storage. In particular, PPARG expression was greatest for low 
temperature and high oxygen (26 °C 20 % oxygen) for all three donors and this correlates 
with the highest number of adipocytes stained. The effect of temperature on FABP4 
expression was also statistically significant for all three donors. 
Valorani et al. showed that culturing adipose derived hMSCs for 7 days under 2 % oxygen 
and 37 °C increases their osteogenic potential (Valorani et al., 2012).  However, data 
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described in chapter 4 showed that, for bone marrow derived hMSCs, exposure to lower 
temperature (26°C) has an even greater effect on enhancing the adipogenic potential.  
 
 
 
5.1.6 DoE as an investigational and decision support tool 
 
A DoE approach was applied to investigate the combined effect of temperature, oxygen and 
storage duration on cartilage discs and the combined effect of temperature and oxygen on 
undifferentiated hMSCs.  This approach was preferred to the OFAT approach as it allows one 
to investigate the effect of interactions between factors and therefore a better understanding 
of how parameters effect the response, such as viability, metabolite concentration in spent 
medium and gene expressions changes. For cartilage disc storage, temperature had a 
statistically significant effect on viability, glucose, lactate, glutamine, ammonia and COL1A1 
expression. Oxygen had a statistically significant effect on glutamine, ammonia concentration 
and COL1A1. Interestingly, oxygen and temperature interaction showed a statistically 
significant effect on lactate metabolism, implying that the temperature mediated decrease in 
lactate released by the cartilage discs will be dependent on the oxygen tension. The effect of 
oxygen on glutamine and ammonia was confirmed but not statistically significant for 
undifferentiated hMSCs storage supporting the important finding that even when subjected to 
the same storage conditions, different cells might react in a different manner. Differences 
were also found in the expression of genes related to the chondrogenic potential of the two 
cell therapy products. The effect of oxygen on COL1A1 was not statistically significant. 
However, its interaction with temperature was statistically significant, showing that oxygen 
will modulate the expression of COL1A1 to a varying extent depending on the storage 
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temperature. Within the multidimensional space under investigation, the effect of different 
oxygen tension (3 and 20 %) was greater for storage at 37 °C than for storage at 26 °C.  
Jakobsen et al. also applied a multifactorial approach to investigate the factors that induce 
chondrogenesis of hMSCs in-vitro (Jakobsen, Ostrup, Zhang, Mikkelsen, & Brinchmann, 
2014). This enabled them to identify the optimal combination of growth factors (TGF- and 
dexamethasone) leading to the highest expression of desirable hyaline cartilage markers. 
However, they found that this optimal combination also introduced an induction of unwanted 
markers, such as an upregulation of COL1A1.  
Similarly, data described in chapter 2 and 3 of this thesis have shown that preferential storage 
conditions for cartilage discs in terms of viability, lactate, ammonia, COL2A1 and ACAN are 
the ones that led to upregulation of COL1A1,  which should be minimal for cartilage-like 
tissue as collagen type I is abundant in bone ECM but nearly absent in hyaline cartilage (B 
Johnstone, Hering, Caplan, Goldberg, & Yoo, 1998). 
This suggests that multiple factors should not be analysed nor controlled independently as the 
preferred outcome might be only achieved by adequately combining input factors. This was 
the basis for the case studies described in chapter 3. The eight response models created using 
the data from cartilage disc storage were combined together. Case study 1 showed how in a 
hypothetic scenario where two storage containers were available, values of viability, glucose, 
lactate, glutamine, ammonia and gene expression changes can be predicted. This simulation 
could be repeated for many more storage containers where temperature, oxygen tension and 
storage duration are the input parameters. This would support the screening phase of 
procurement for a storage container. Although the ‘shortlisted’ containers will then need to be 
tested and validated, the approach described in the case study will considerably reduce time 
and costs.  
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Case study 2 showed how the response models can be combined to predict the values that 
temperature and oxygen should have given set product specifications and assuming storage 
duration of 7 days. This hypothetical scenario represents the case where a storage container is 
not available for the cell therapy product and it aims to support its design. An ‘optimal’ 
operational space was identified and it includes all combinations of temperature and oxygen 
that are likely to meet the product specifications following 7 day storage.  
As a decision support tool, DoE has the potential to limit the number of experiments required 
while maximising the understanding of multifactorial effect on the cell therapy product. This 
can be particularly useful where the amount of ‘raw’ material available for testing is limited, 
such as for autologous products (C. K. Schneider et al., 2010).  
A similar approach has been suggested by Chen et al. for the characterization and 
optimization of cell seeding in scaffold for skeletal tissue engineering (Y. Chen et al., 2011). 
 
 
 
5.2 Challenges and limitations    
 
Data described in chapter 2 and 4 showed considerable donor to donor variability. The 
selection of ‘young healthy donors’ of Caucasian ethnicity to isolate bone marrow and 
hMSCs is very common among the scientific community. However, bone marrow and 
hMSCs isolated from this class of donors might be, in reality, very heterogeneous (Phinney & 
Prockop, 2007). 
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Given the inter donor variability observed in the data, the analysis of results was based on a 
technique known as ‘blocking’, which allows for more precise evaluation of main effects and 
interactions (Montgomery, 2012). It was not within the scope of this thesis to investigate the 
biological difference between donors. However, in order to increase the statistical power, at 
least two more donors could be tested.  
In terms of biological differences between donors, it is important to consider its impact on 
process development of cell based medicinal products. For allogeneic therapies, hMSCs are 
expanded from one ‘universal’ donor to produce multiple doses for more patients. A master 
cell bank is normally developed (Salmikangas et al., 2015) as described in chapter 1. Bone 
marrow, or potentially any other source of biological material, is tested for safety (i.e. 
absence of pathogens). hMSCs derived from this donor can be extensively characterized 
during product development and a baseline can be generated. If a new donor needs to be 
introduced to comply with the demand of the product, the hMSCs will be characterized and 
compared with the baseline generated from the first donor. Only if no statistical significance 
can be observed, will the second donor will be used for production. The characterization 
should go beyond ISCT guidelines. If the product is the cartilage disc studied in this thesis, 
one additional parameter to monitor should be cell proliferation during chondrogenesis as 
high cell density correlates with better chondrogenesis (Murdoch et al., 2007). 
All the storage experiments described in this thesis were carried out using tissue culture 
incubators where temperature and oxygen could be reproducibly set to specific levels. As 
only 4 dedicated incubators were available, it was not possible to confirm the presence of a 
non-linear relationship between the input parameters (temperature, oxygen and storage 
duration) and the output variables (viability, metabolites and gene expression). This would 
have required at least one additional storage condition and, therefore, at least one additional 
dedicated tissue culture incubator.  
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5.3 Future work  
 
The work described in this thesis could be further developed as described below: 
 
 As shown in Chapters 3 and 4, the concentration of ammonia in the spent medium 
following storage at 26 and 37 °C could be effectively reduced by lowering the 
oxygen level from 20 % to 3%. Building on this important finding, a new primary 
container for the storage of a cell-based product could be developed. The storage 
experiments described in this thesis were performed using culture plates or flasks as 
primary containers where the headspace was in equilibrium with the chamber of the 
incubator. If the oxygen tension was set at 3 %, this was kept constant within the 
incubator. In order to develop the primary container as mentioned above, the oxygen 
and carbon dioxide within the medium should be measured over 7 day storage at 26 
and 37 °C and compared with the values of the same culture plate after being 
adequately sealed. If a significant drop in oxygen level is detected compared to the 
open container, then a ‘passive’ system could be devised to enable the oxygen tension 
to be constant for the duration of the storage. This would include a membrane with 
specific diffusion coefficient which would separate the sample from an “enriched” 
oxygen headspace (Fig 5.1). An optical patch could also be placed within the primary 
container to enable non-invasive oxygen monitoring during storage and 
transportation. Temperature monitoring is currently a requirement for transportation 
of temperature sensitive medicinal products. As standards for cell-based medicinal 
product transportation are developed, oxygen monitoring might prove necessary to 
ensure the quality of the product is not altered for non-cryopreserved products.  
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Fig. 5.1 Schematic of an innovative primary container for the storage and 
transportation of cell and tissue products. The oxygen ‘enriched’ chamber would 
provide through the membrane the adequate oxygen supply for the effective 
preservation of viability and biological function of the product.  
 
 
 Data described in chapter 4 for the storage of undifferentiated hMSCs were generated 
using T25 flasks and culture plates. This provides the cells a surface to adhere to 
which does not normally occur when the cells are stored and transported in vials, bags 
or syringes. On the other hand, it is reasonable to assume that maintaining adherent 
cells in a more natural state would contribute to the preservation of their biological 
properties.  This hypothesis is also supported from the ‘protective’ effect exerted by 
the ECM or biomaterials on cells, discussed earlier in this chapter. The potential 
beneficial effect of hMSC attachment during storage could be tested. If this 
hypothesis is confirmed, a new primary container could be devised which 
incorporates a temperature-sensitive polymer. This would allow for the cells to attach 
during storage and transportation and detach by adequately changing the temperature 
for delivery and administration of the product, negating the need for an enzymatic-
mediated detachment reaction, which may not be optimal in a clinical setting. This 
approach is based on a technology developed by Professor Teruo Okano and currently 
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used to grow cells to confluency and detach them as a single sheet by lowering the 
temperature (J. Yang et al., 2005). 
 
 The advantages of storing a cell therapy product between 26 and 37 °C could be 
compared with temperature that are commonly used for the transport of 
pharmaceuticals, such as controlled room temperature, hypothermic and -20 °C (Fig. 
5.2). Chapter 3 demonstrated that the viability of the cartilage discs decreased as 
storage temperature increased for both a 5 and 7 day shelf life. However, storage and 
transport at a temperature that is closer to physiological, might significantly improve 
the preservation of the product’s biological properties by limiting cold-induced stress. 
This hypothesis is also supported by data described in chapters 2 and 4; both cartilage 
discs and hMSCs showed enhanced expression of COL2A1 and reduced COL1A1 
when stored at 37 °C and 20 % oxygen. However, this chondrogenic potential should 
be further investigated by introducing a protein level assays (such as western blotting 
or ELISA), in order to confirm that higher expression of COL2A1 corresponds to 
higher production of collagen type II. Moreover, a live-dead staining of the cartilage 
discs following storage could also be introduced to provide additional information on 
the ‘health’ status of the cells within the disc. This could be used in combination with 
results generated from the Alamar blue assay and enable a better viability assessment.  
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Fig. 5.2 Schematic illustration of the main temperature ranges that can be adopted for the 
transportation of pharmaceutical products.  
 
 
 
 Although this research project was focused on storage, the results highlighted the 
potential for improvement of the current manufacturing process for a cell-based 
product. Mendicino et al., as part of a FDA review, reported that one of the main 
factors that can influence the manufacturing of hMSCs is the oxygen tension 
(Mendicino et al., 2014). The adoption of oxygen tension different than atmospheric 
(21%) has been successfully adopted for enhanced expansion of multipotent adult 
progenitor cells (MAPCs), where the cells are expanded at 3% oxygen (Subramanian, 
Park, Verfaillie, & Hu, 2011). Moreover, such hypoxic culture conditions can be used 
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to enhance the secretion of trophic factors, as already shown by Chang et al (2013)  
(Chang et al., 2013). The combined effect of temperature between 26 °C and 37 °C 
and oxygen could pave the way to innovative manufacturing processes which 
modulate the biological properties of the cells, including the production of trophic 
factors. Such approach is currently being investigated for robust production of hESCs 
and iPSCs (Silva et al., 2015). 
 
 
5.4 Conclusion 
 
The cell therapy market is growing at a fast pace and an increasing number of products are 
approaching late clinical development and the commercial phase. The preservation of the 
biological properties of a cell-based medicinal product throughout the supply chain will be 
paramount and effective solutions for storage and transportation will require deeper 
understanding and characterization of how these products are affected by process parameters.  
This thesis demonstrates that within the normothermic range investigated in this thesis (26 °C 
and 37 °C), temperature and oxygen can modulate the properties of cartilage discs and 
undifferentiated hMSCs over a simulated shelf-life of 5 and 7 days.  
The use of a DoE based approach as an investigation tool permitted the identification of 
interactions between temperature and oxygen that are very common for bioprocess systems.  
The cell therapy industry is going through a similar product development path that traditional 
biopharmaceuticals faced 20 years ago. Similarly to what occurred for protein-based drug 
manufacturing, enhanced knowledge of the parameters that affect the cell during storage and 
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transportation will be necessary in order to realize the full potential of human cells as living 
therapeutic agents.  
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Appendix I  
 
Donor details for the bone marrow derived hMSCs used in this thesis 
 
Donor Sex Ethnicity Age 
1 Female Caucasian 24 
2 Male Caucasian 29 
3 Male Caucasian 25 
 
 
 
 
 
 
